How were new medicines discovered?

Nature Reviews Drug Discovery 10, 507-519

DOI: 10.1038/nrd3480

Citation Report

#	Article	IF	CITATIONS
1	Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Canadian Journal of Physiology and Pharmacology, 1977, 55, 48-51.	0.7	410
2	Medicinal chemistry for 2020. Future Medicinal Chemistry, 2011, 3, 1765-1786.	1.1	35
3	Identifying Compound-Target Associations by Combining Bioactivity Profile Similarity Search and Public Databases Mining. Journal of Chemical Information and Modeling, 2011, 51, 2440-2448.	2.5	71
4	Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discovery Today: Therapeutic Strategies, 2011, 8, 85-88.	0.5	38
5	Nanoparticle-Mediated Measurement of Target–Drug Binding in Cancer Cells. ACS Nano, 2011, 5, 9216-9224.	7.3	21
6	The development of label-free cellular assays for drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 1285-1298.	2.5	54
7	Drug Discovery into the 21st Century., 0,,.		O
8	Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives. Oxidative Medicine and Cellular Longevity, 2011, 2011, 1-14.	1.9	222
9	Evolutionary Biology and Drug Development. , 0, , .		0
10	From 3D cell culture to organs-on-chips. Trends in Cell Biology, 2011, 21, 745-754.	3.6	1,514
10	From 3D cell culture to organs-on-chips. Trends in Cell Biology, 2011, 21, 745-754.  News in brief: Biomedical briefing. Nature Medicine, 2011, 17, 910-911.	3.6 15.2	1,514 0
11	News in brief: Biomedical briefing. Nature Medicine, 2011, 17, 910-911.  Strategies to generate biological reagents for kinase drug discovery. Expert Opinion on Drug	15.2	0
11	News in brief: Biomedical briefing. Nature Medicine, 2011, 17, 910-911.  Strategies to generate biological reagents for kinase drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 1215-1225.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for	15.2 2.5	0
11 12 13	News in brief: Biomedical briefing. Nature Medicine, 2011, 17, 910-911.  Strategies to generate biological reagents for kinase drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 1215-1225.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases. PLoS Neglected Tropical Diseases, 2012, 6, e1762.  In VivoChemical Screening for Modulators of Hematopoiesis and Hematological Diseases. Advances in	15.2 2.5 1.3	0 1 93
11 12 13	News in brief: Biomedical briefing. Nature Medicine, 2011, 17, 910-911.  Strategies to generate biological reagents for kinase drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 1215-1225.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases. PLoS Neglected Tropical Diseases, 2012, 6, e1762.  In VivoChemical Screening for Modulators of Hematopoiesis and Hematological Diseases. Advances in Hematology, 2012, 2012, 1-12.  A simple statistical test to infer the causality of target/phenotype correlation from small molecule	15.2 2.5 1.3	0 1 93 3
11 12 13 14	News in brief: Biomedical briefing. Nature Medicine, 2011, 17, 910-911.  Strategies to generate biological reagents for kinase drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 1215-1225.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases. PLoS Neglected Tropical Diseases, 2012, 6, e1762.  In VivoChemical Screening for Modulators of Hematopoiesis and Hematological Diseases. Advances in Hematology, 2012, 2012, 1-12.  A simple statistical test to infer the causality of target/phenotype correlation from small molecule phenotypic screens. Bioinformatics, 2012, 28, 301-305.	15.2 2.5 1.3 0.6	0 1 93 3

#	Article	IF	Citations
19	Network pharmacology for cancer drug discovery: are we there yet?. Future Medicinal Chemistry, 2012, 4, 939-941.	1.1	42
20	An alternative approach to drug discovery for Alzheimer's disease dementia. Future Medicinal Chemistry, 2012, 4, 1681-1688.	1.1	32
21	Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus $\hat{A}$	1.1	21
22	Pharmaceutical structure montages as catalysts for design and discovery. Future Medicinal Chemistry, 2012, 4, 951-954.	1.1	1
23	7th Annual European Antibody Congress 2011. MAbs, 2012, 4, 134-152.	2.6	7
24	Systems drug discovery: a quantitative, objective approach for safer drug development. Expert Opinion on Drug Discovery, 2012, 7, 757-759.	2.5	5
25	Novel Stem Cell–Based Drug Discovery Platforms for Cardiovascular Disease. Journal of Biomolecular Screening, 2012, 17, 1117-1127.	2.6	5
26	Partnering with the professor. Nature Biotechnology, 2012, 30, 944-952.	9.4	12
27	Development of Drugs from Plants. Advances in Botanical Research, 2012, 62, 385-408.	0.5	0
28	Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2665-74.	<b>3.</b> 3	64
29	Cell biology: A key driver of therapeutic innovation. Journal of Cell Biology, 2012, 199, 571-575.	2.3	2
30	Recruitment of Brown Adipose Tissue as a Therapy for Obesity-Associated Diseases. Frontiers in Endocrinology, 2012, 3, 14.	1.5	62
31	Phenotypic and <i>In Vivo</i> Screening: Lead Discovery and Drug Repurposing. RSC Drug Discovery Series, 2012, , 86-93.	0.2	4
32	Future directions in phosphodiesterase drug discovery. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6794-6800.	1.0	28
33	Discovery of Inhibitors of Microglial Neurotoxicity Acting Through Multiple Mechanisms Using a Stem-Cell-Based Phenotypic Assay. Cell Stem Cell, 2012, 11, 620-632.	5.2	75
34	Immunogenicity to Biologics: Mechanisms, Prediction and Reduction. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 331-344.	1.0	99
35	Centralized mouse repositories. Mammalian Genome, 2012, 23, 559-571.	1.0	25
36	Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 11-19.	1.4	214

#	ARTICLE	IF	CITATIONS
37	Reconsidering phenotypic heart failure drug discovery. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e199-e203.	0.5	0
38	Recycling side-effects into clinical markers for drug repositioning. Genome Medicine, 2012, 4, 3.	3.6	39
39	Identifying mechanism-of-action targets for drugs and probes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11178-11183.	3.3	156
40	<i>In Vitro</i> Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors.  Journal of the American Chemical Society, 2012, 134, 10469-10477.	6.6	209
41	Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists. ACS Medicinal Chemistry Letters, 2012, 3, 165-169.	1.3	30
42	The Valley of Death in anticancer drug development: a reassessment. Trends in Pharmacological Sciences, 2012, 33, 173-180.	4.0	80
43	Fully Functionalized Small-Molecule Probes for Integrated Phenotypic Screening and Target Identification. Journal of the American Chemical Society, 2012, 134, 10385-10388.	6.6	89
44	Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds. Journal of Medicinal Chemistry, 2012, 55, 4877-4895.	2.9	180
45	Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 2012, 11, 191-200.	21.5	1,520
46	System-based drug discovery within the human kinome. Expert Opinion on Drug Discovery, 2012, 7, 1053-1070.	2.5	32
47	A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5579-5583.	1.0	20
48	Metabolic Disease Drug Discovery— "Hitting the Target―ls Easier Said Than Done. Cell Metabolism, 2012, 15, 19-24.	7.2	35
49	Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discovery Today, 2012, 17, 1088-1102.	3.2	356
50	MAPKAP Kinase 2 (MK2) as a Target for Anti-inflammatory Drug Discovery. RSC Drug Discovery Series, 2012, , 158-180.	0.2	3
51	Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Current Opinion in Biotechnology, 2012, 23, 609-616.	3.3	86
52	Future strategies in epigenetic drug discovery. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e121-e127.	0.5	10
53	What is the most important approach in current drug discovery: doing the right things or doing things right?. Drug Discovery Today, 2012, 17, 1166-1169.	3.2	21
54	Small Molecule Bromodomain Inhibitors. Progress in Medicinal Chemistry, 2012, 51, 1-55.	4.1	39

#	ARTICLE	IF	Citations
55	An update of novel screening methods for GPCR in drug discovery. Expert Opinion on Drug Discovery, 2012, 7, 791-806.	2.5	29
56	Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 3614-3643.	2.9	79
57	NCATS launches drug repurposing program. Nature Biotechnology, 2012, 30, 571-572.	9.4	88
58	Phenotypic screening, take two. Science-Business EXchange, 2012, 5, 380-380.	0.0	54
60	<i>Plasmodium</i> kinases as targets for new-generation antimalarials. Future Medicinal Chemistry, 2012, 4, 2295-2310.	1.1	85
61	A comparative analysis of the molecular topologies for drugs, clinical candidates, natural products, human metabolites and general bioactive compounds. MedChemComm, 2012, 3, 312-321.	3 <b>.</b> 5	32
62	Label-Free Phenotypic Profiling Identified D-Luciferin as a GPR35 Agonist. PLoS ONE, 2012, 7, e34934.	1.1	24
63	High Throughput Screening for Small Molecule Enhancers of the Interferon Signaling Pathway to Drive Next-Generation Antiviral Drug Discovery. PLoS ONE, 2012, 7, e36594.	1.1	46
64	Forward Chemical Genetics in Yeast for Discovery of Chemical Probes Targeting Metabolism. Molecules, 2012, 17, 13098-13115.	1.7	14
65	Network Pharmacology and Traditional Chinese Medicine. , 2012, , .		6
66	Future Antibiotic Agents: Turning to Nature for Inspiration. , 2012, , .		2
67	Section summary and perspectives: Translational medicine in neurology. , 0, , 253-260.		O
69	Perspectives on the Discovery of Small-Molecule Modulators for Epigenetic Processes. Journal of Biomolecular Screening, 2012, 17, 555-571.	2.6	21
70	Bioinformatics and variability in drug response: a protein structural perspective. Journal of the Royal Society Interface, 2012, 9, 1409-1437.	1.5	66
71	Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy. Journal of Medicinal Chemistry, 2012, 55, 4527-4538.	2.9	183
72	Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery. Journal of Medicinal Chemistry, 2012, 55, 576-586.	2.9	182
73	Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nature Reviews Drug Discovery, 2012, 11, 355-365.	21.5	334
74	Structural enrichment of HTS compounds from available commercial libraries. MedChemComm, 2012, 3, 571.	3.5	13

#	Article	IF	CITATIONS
75	Chapter 12. Expanding the Target Space: Druggability Assessments. RSC Drug Discovery Series, 2012, , $302-318$ .	0.2	0
76	Drug Molecules and Biology: Network and Systems Aspects. RSC Drug Discovery Series, 2012, , 32-49.	0.2	6
77	Biosynthetic medicinal chemistry of natural product drugs. MedChemComm, 2012, 3, 854.	3.5	37
78	A Quantitative Systems Pharmacology Computer Model for Schizophrenia Efficacy and Extrapyramidal Side Effects. Drug Development Research, 2012, 73, 196-213.	1.4	21
79	Small zebrafish in a big chemical pond. Journal of Cellular Biochemistry, 2012, 113, 2208-2216.	1.2	15
81	Discovery and Target Identification of an Antiproliferative Agent in Live Cells Using Fluorescence Difference in Twoâ€Dimensional Gel Electrophoresis. Angewandte Chemie - International Edition, 2012, 51, 5447-5451.	7.2	62
82	Syntheses and Cell-Based Phenotypic Screen of Novel 7-Amino pyrido [2,3-d] pyrimidine-6-carbonitrile Derivatives as Potential Antiproliferative Agents. Molecules, 2012, 17, 2351-2366.	1.7	11
83	Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms. Journal of Chemical Information and Modeling, 2012, 52, 617-648.	2.5	246
84	Biomarker science: on a theme of personalized medicine. Journal of Thrombosis and Thrombolysis, 2012, 34, 141-142.	1.0	2
85	Established and Emerging Trends in Computational Drug Discovery in the Structural Genomics Era. Chemistry and Biology, 2012, 19, 29-41.	6.2	57
86	Lessons from the Past and Charting the Future of Marine Natural Products Drug Discovery and Chemical Biology. Chemistry and Biology, 2012, 19, 85-98.	6.2	523
87	How Chemoproteomics Can Enable Drug Discovery and Development. Chemistry and Biology, 2012, 19, 11-22.	6.2	137
88	Global Phenotypic Screening for Antimalarials. Chemistry and Biology, 2012, 19, 116-129.	6.2	120
89	Pathways and targets—opposite approaches to success?. Drug Discovery Today, 2012, 17, 183-184.	3.2	0
90	Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discovery Today, 2012, 17, 475-485.	3.2	172
91	Translational semantics and infrastructure: another search for the emperor's new clothes?. Drug Discovery Today, 2012, 17, 459-468.	3.2	29
92	Chemoproteomic approaches to drug target identification and drug profiling. Bioorganic and Medicinal Chemistry, 2012, 20, 1973-1978.	1.4	88
93	Screening for small molecule inhibitors of embryonic pathways: Sometimes you gotta crack a few eggs. Bioorganic and Medicinal Chemistry, 2012, 20, 1869-1877.	1.4	9

#	Article	IF	CITATIONS
94	Synthesis and pharmacological evaluation of carbamic acid 1-phenyl-3-(4-phenyl-piperazine-1-yl)-propyl ester derivatives as new analgesic agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2434-2439.	1.0	20
96	A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. Journal of Virological Methods, 2012, 183, 176-179.	1.0	30
97	Experimental validation of in silico target predictions on synergistic protein targets. Journal of Cheminformatics, $2013, 5, \ldots$	2.8	0
98	Phenotypic screens as a renewed approach for drug discovery. Drug Discovery Today, 2013, 18, 1067-1073.	3.2	363
99	Structureâ€"Activity Studies of Divin: An Inhibitor of Bacterial Cell Division. ACS Medicinal Chemistry Letters, 2013, 4, 880-885.	1.3	13
100	Metabolically re-modeling the drug pipeline. Current Opinion in Pharmacology, 2013, 13, 778-785.	1.7	33
101	Surface Plasmon Resonance in Binding Site, Kinetic, and Concentration Analyses., 2013,, 209-221.		4
102	Translational research policies: disruptions and continuities in biomedical innovation systems in Austria, Finland and Germany. Journal of Community Genetics, 2013, 4, 189-201.	0.5	15
103	Combining phenotypic and proteomic approaches to identify membrane targets in a †triple negative†triple breast cancer cell type. Molecular Cancer, 2013, 12, 11.	7.9	48
104	A Novel Reporter System for Molecular Imaging and Highâ€Throughput Screening of Anticancer Drugs. ChemBioChem, 2013, 14, 1494-1503.	1.3	6
105	Discovery of a potent anti-tumor agent through regioselective mono-N-acylation of 7H-pyrrolo[3,2-f]quinazoline-1,3-diamine. MedChemComm, 2013, 4, 1275.	3.5	11
106	Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family. BMC Pharmacology & David Pharmacology & Pharma	1.0	29
107	Phenotypic Screening as a Strategic Component of Drug Discovery Programs Targeting Novel Antiparasitic and Antimycobacterial Agents: An Editorial. Journal of Medicinal Chemistry, 2013, 56, 7715-7718.	2.9	24
108	Oligodendrocyte N-Methyl-d-aspartate Receptor Signaling: Insights into Its Functions. Molecular Neurobiology, 2013, 47, 845-856.	1.9	12
109	HDAC inhibitors in kidney development and disease. Pediatric Nephrology, 2013, 28, 1909-1921.	0.9	52
110	Polypharmacology – Foe or Friend?. Journal of Medicinal Chemistry, 2013, 56, 8955-8971.	2.9	399
111	In Silico Target Predictions: Defining a Benchmarking Data Set and Comparison of Performance of the Multiclass NaÃ-ve Bayes and Parzen-Rosenblatt Window. Journal of Chemical Information and Modeling, 2013, 53, 1957-1966.	2.5	131
112	The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing. European Journal of Medicinal Chemistry, 2013, 62, 777-784.	2.6	44

#	ARTICLE	IF	CITATIONS
113	Cellular Assays for Drug Discovery in Genetic Disorders of Intracellular Trafficking. Annual Review of Genomics and Human Genetics, 2013, 14, 159-190.	2.5	11
114	Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches. Journal of Medicinal Chemistry, 2013, 56, 7719-7726.	2.9	158
115	Computational Profiling of Bioactive Compounds Using a Target-Dependent Composite Workflow. Journal of Chemical Information and Modeling, 2013, 53, 2322-2333.	2.5	29
116	A Moment of Reflection: Sixty Years After the Nobel Prize for Hermann Staudinger. Advances in Polymer Science, 2013, , 1-19.	0.4	4
118	Novel approaches in antimalarial drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 1325-1337.	2.5	15
119	Target deconvolution techniques in modern phenotypic profiling. Current Opinion in Chemical Biology, 2013, 17, 118-126.	2.8	137
120	Identification and Rescue of α-Synuclein Toxicity in Parkinson Patient–Derived Neurons. Science, 2013, 342, 983-987.	6.0	416
122	Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches. Journal of Biomolecular Screening, 2013, 18, 1143-1155.	2.6	109
123	Clinical Relevance of Target Identity and Biology. Journal of Biomolecular Screening, 2013, 18, 1164-1185.	2.6	7
124	Future Viable Models of Psychiatry Drug Discovery in Pharma. Journal of Biomolecular Screening, 2013, 18, 509-521.	2.6	14
125	Antimalarial drug discovery $\hat{a} \in \text{``approaches}$ and progress towards new medicines. Nature Reviews Microbiology, 2013, 11, 849-862.	13.6	244
126	Privileged Substructure-Based Diversity-Oriented Synthesis Pathway for Diverse Pyrimidine-Embedded Polyheterocycles. Organic Letters, 2013, 15, 5814-5817.	2.4	34
128	Chemical profiling of deoxyhypusine hydroxylase inhibitors for antimalarial therapy. Amino Acids, 2013, 45, 1047-1053.	1.2	8
129	Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2133-2140.	1.2	100
130	Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease. Drug Discovery Today: Technologies, 2013, 10, e121-e128.	4.0	24
131	Recent Advances in Small Molecule Target Identification Methods. Annual Reports in Medicinal Chemistry, 2013, , 301-315.	0.5	0
132	Working Memory Impairment in Calcineurin Knock-out Mice Is Associated with Alterations in Synaptic Vesicle Cycling and Disruption of High-Frequency Synaptic and Network Activity in Prefrontal Cortex. Journal of Neuroscience, 2013, 33, 10938-10949.	1.7	41
133	Synthetic Macrocycles in Small-Molecule Drug Discovery. Annual Reports in Medicinal Chemistry, 2013, , 371-386.	0.5	17

#	Article	IF	CITATIONS
134	Experimental validation of <i>in silico</i> target predictions on synergistic protein targets. MedChemComm, 2013, 4, 278-288.	3.5	7
135	Segmenting the Etiological Agent of Schistosomiasis for High-Content Screening. IEEE Transactions on Medical Imaging, 2013, 32, 1007-1018.	5.4	14
136	How can attrition rates be reduced in cancer drug discovery?. Expert Opinion on Drug Discovery, 2013, 8, 363-368.	2.5	97
137	Yeast Reveal a "Druggable―Rsp5/Nedd4 Network that Ameliorates α-Synuclein Toxicity in Neurons. Science, 2013, 342, 979-983.	6.0	234
138	Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nature Chemical Biology, 2013, 9, 97-104.	3.9	161
139	A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. Nature Chemistry, 2013, 5, 195-202.	6.6	270
140	Target identification of small molecules based on chemical biology approaches. Molecular BioSystems, 2013, 9, 897.	2.9	74
141	Streamlining Chemical Probe Discovery: Libraries of "Fully Functionalized―Small Molecules for Phenotypic Screening. Angewandte Chemie - International Edition, 2013, 52, 1368-1370.	7.2	13
142	Regulating the ARNT/TACC3 Axis: Multiple Approaches to Manipulating Protein/Protein Interactions with Small Molecules. ACS Chemical Biology, 2013, 8, 626-635.	1.6	37
143	Novel Screening Assay for the Selective Detection of G-Protein-Coupled Receptor Heteromer Signaling. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 179-188.	1.3	16
145	In vivo strategies for drug discovery in myotonic dystrophy disorders. Drug Discovery Today: Technologies, 2013, 10, e97-e102.	4.0	1
146	Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. Chemistry and Biology, 2013, 20, 1352-1363.	6.2	72
147	Development of High-Content Assays for Kidney Progenitor Cell Expansion in Transgenic Zebrafish. Journal of Biomolecular Screening, 2013, 18, 1193-1202.	2.6	26
149	Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. Journal of Pharmacological and Toxicological Methods, 2013, 67, 69-81.	0.3	35
150	Lifespan extension of rotifers by treatment with red algal extracts. Experimental Gerontology, 2013, 48, 1420-1427.	1.2	24
151	What general conclusions can we draw from kinase profiling data sets?. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1425-1433.	1.1	28
152	Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 530-549.	2.0	167
153	Chemogenomic Profiling. , 2013, , 153-176.		3

#	Article	IF	CITATIONS
154	Target identification and mechanism of action in chemical biology and drug discovery. Nature Chemical Biology, 2013, 9, 232-240.	3.9	814
155	Systems-level antimicrobial drug and drug synergy discovery. Nature Chemical Biology, 2013, 9, 222-231.	3.9	146
156	Discovery of a highly selective FLT3 kinase inhibitor from phenotypic cell viability profiling. MedChemComm, 2013, 4, 228-232.	3.5	4
157	Druggability predictions: methods, limitations, and applications. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2013, 3, 327-338.	6.2	30
158	Expanding medicinal chemistry space. Drug Discovery Today, 2013, 18, 298-304.	3.2	78
159	Chemogenomics Approaches to Rationalizing the Mode-of-Action of Traditional Chinese and Ayurvedic Medicines. Journal of Chemical Information and Modeling, 2013, 53, 661-673.	2.5	51
160	Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack. Angewandte Chemie - International Edition, 2013, 52, 2744-2792.	7.2	393
161	Computational Drug Repositioning: From Data to Therapeutics. Clinical Pharmacology and Therapeutics, 2013, 93, 335-341.	2.3	321
162	The why and how of phenotypic small-molecule screens. Nature Chemical Biology, 2013, 9, 206-209.	3.9	113
163	Challenges and approaches for the development of safer immunomodulatory biologics. Nature Reviews Drug Discovery, 2013, 12, 306-324.	21.5	138
164	"Function-First―Lead Discovery: Mode of Action Profiling of Natural Product Libraries Using Image-Based Screening. Chemistry and Biology, 2013, 20, 285-295.	6.2	89
165	Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS Journal, 2013, 280, 5957-5980.	2.2	95
166	Synthesis of Molecular Frameworks Containing Two Distinct Heterocycles Connected in a Single Molecule with Enhanced Threeâ€Dimensional Shape Diversity. Chemistry - A European Journal, 2013, 19, 7100-7108.	1.7	8
167	Drug Discovery from Marine Microbes. Microbial Ecology, 2013, 65, 800-806.	1.4	104
168	Integration of Chemical and RNAi Multiparametric Profiles Identifies Triggers of Intracellular Mycobacterial Killing. Cell Host and Microbe, 2013, 13, 129-142.	5.1	74
169	Label-free monitoring of T cell activation by the impedance-based xCELLigence system. Molecular BioSystems, 2013, 9, 1035.	2.9	24
170	Systems-Based Discovery Advances Drug Development. Clinical Pharmacology and Therapeutics, 2013, 93, 285-287.	2.3	9
171	Interactions between cellular proteins and morphologically different nanoscale aggregates of small molecules. RSC Advances, 2013, 3, 7704.	1.7	30

#	Article	IF	CITATIONS
172	Kidney failure: aims for the next 10 years and barriers to success. Lancet, The, 2013, 382, 353-362.	6.3	50
173	Predictive methods in drug repurposing: gold mine or just a bigger haystack?. Drug Discovery Today, 2013, 18, 523-532.	3.2	46
174	Integrating Human Pluripotent Stem Cells into Drug Development. Cell Stem Cell, 2013, 12, 669-677.	5.2	123
175	Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines. Clinical Pharmacology and Therapeutics, 2013, 93, 299-301.	2.3	344
176	A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels. Molecular BioSystems, 2013, 9, 1381.	2.9	35
177	From noncovalent to covalent bonds: a paradigm shift in target protein identification. Molecular BioSystems, 2013, 9, 544.	2.9	28
178	A black hole for oxidized glutathione. Nature Chemical Biology, 2013, 9, 69-70.	3.9	12
179	Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discovery Today, 2013, 18, 211-217.	3.2	93
180	Neural stem cells as tools for drug discovery: novel platforms and approaches. Expert Opinion on Drug Discovery, 2013, 8, 1083-1094.	2.5	19
181	Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development. Chemistry and Biology, 2013, 20, 674-684.	6.2	42
182	G-protein-coupled receptor regulation of <i>de novo</i> purine biosynthesis: a novel druggable mechanism. Biotechnology and Genetic Engineering Reviews, 2013, 29, 31-48.	2.4	15
183	The Chemical Basis of Serine Palmitoyltransferase Inhibition by Myriocin. Journal of the American Chemical Society, 2013, 135, 14276-14285.	6.6	98
184	Chemical Interrogation of the Neuronal Kinome Using a Primary Cell-Based Screening Assay. ACS Chemical Biology, 2013, 8, 1027-1036.	1.6	40
186	Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery. Circulation Research, 2013, 112, 534-548.	2.0	99
187	Drug discovery goes for a swim. Nature Chemical Biology, 2013, 9, 68-69.	3.9	5
188	Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives. Current Pharmaceutical Design, 2013, 19, 578-613.	0.9	69
189	Using a systems-based approach to overcome reductionist strategies in the development of diagnostics. Expert Review of Molecular Diagnostics, 2013, 13, 895-905.	1.5	6
190	Using economic optimization to design high-throughput screens. Future Medicinal Chemistry, 2013, 5, 9-11.	1.1	2

#	Article	IF	CITATIONS
191	An Exploratory Evaluation of Tyrosine Hydroxylase Inhibition in Planaria as a Model for Parkinsonism. International Journal of Molecular Sciences, 2013, 14, 23289-23296.	1.8	7
192	The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines. Journal of Biomolecular Screening, 2013, 18, 1186-1192.	2.6	62
193	Building Predictive Models for Mechanism-of-Action Classification from Phenotypic Assay Data Sets. Journal of Biomolecular Screening, 2013, 18, 1260-1269.	2.6	41
194	Comparison of Methods for Image-Based Profiling of Cellular Morphological Responses to Small-Molecule Treatment. Journal of Biomolecular Screening, 2013, 18, 1321-1329.	2.6	166
195	The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert Review of Clinical Pharmacology, 2013, 6, 23-34.	1.3	19
196	Perspective on the Discovery and Scientific Impact of p38 MAP Kinase. Journal of Biomolecular Screening, 2013, 18, 1156-1163.	2.6	30
197	Techno-commercial Aspects of Relevance to Red Beet. , 2013, , 409-426.		2
198	Benchmarking of Multivariate Similarity Measures for High-Content Screening Fingerprints in Phenotypic Drug Discovery. Journal of Biomolecular Screening, 2013, 18, 1284-1297.	2.6	32
199	Anticancer Effects of Niclosamide in Human Glioblastoma. Clinical Cancer Research, 2013, 19, 4124-4136.	3.2	135
200	Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?. Future Medicinal Chemistry, 2013, 5, 5-7.	1.1	22
201	Chemical screening identifies filastatin, a small molecule inhibitor of <i>Candida albicans</i> adhesion, morphogenesis, and pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13594-13599.	3.3	95
202	Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open, 2013, 3, e002672.	0.8	74
203	High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?. Expert Opinion on Drug Discovery, 2013, 8, 1449-1453.	2.5	11
205	New Zealand's Drug Development Industry. International Journal of Environmental Research and Public Health, 2013, 10, 4339-4351.	1.2	6
209	Strategies for the Discovery and Development of Anti-Diabetic Drugs from the Natural Products of Traditional Medicines. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 207.	0.9	22
210	New Targets for Drug Discovery against Malaria. PLoS ONE, 2013, 8, e59968.	1.1	18
211	RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist. PLoS ONE, 2013, 8, e83190.	1.1	168
212	A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease. Frontiers in Pharmacology, 2013, 4, 47.	1.6	25

#	Article	IF	CITATIONS
213	Drug discovery and development., 2013,, 321-334.		1
214	Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments. Journal of Parkinson's Disease, 2013, 3, 231-239.	1.5	35
215	New In Vitro Phenotypic Assay for Epilepsy: Fluorescent Measurement of Synchronized Neuronal Calcium Oscillations. PLoS ONE, 2014, 9, e84755.	1.1	46
216	Physiological Normoxia and Absence of EGF Is Required for the Long-Term Propagation of Anterior Neural Precursors from Human Pluripotent Cells. PLoS ONE, 2014, 9, e85932.	1.1	47
217	Quinone Methides as DNA Alkylating Agents: An Overview on Efficient Activation Protocols for Enhanced Target Selectivity. Current Organic Chemistry, 2014, 18, 19-43.	0.9	47
218	Label-free drug discovery. Frontiers in Pharmacology, 2014, 5, 52.	1.6	66
219	Human pluripotent stem cells on artificial microenvironments: a high content perspective. Frontiers in Pharmacology, 2014, 5, 150.	1.6	12
220	Chemo Proteomics, a Valuable Tool for Biomarker and Drug Discovery. Molecular Biology (Los) Tj ETQq1 1 0.784	314.rgBT /	Oyerlock 10
222	The development of acamprosate as a treatment against alcohol relapse. Expert Opinion on Drug Discovery, 2014, 9, 1355-1369.	2.5	14
223	New perspectives on the use of nucleic acids in pharmacological applications: inhibitory action of extracellular self-DNA in biological systems. Phytochemistry Reviews, 2014, 13, 937-946.	3.1	13
224	Insect Acetylcholinesterase as a Target for Effective and Environmentally Safe Insecticides. Advances in Insect Physiology, 2014, , 435-494.	1.1	21
225	Protein–protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays. Expert Opinion on Drug Discovery, 2014, 9, 1393-1404.	2.5	36
226	Novel methods and approaches to acute lymphoblastic leukemia drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 1435-1446.	2.5	8
227	The use of high-throughput screening in identifying chemotherapeutic agents for gastric cancer. Future Medicinal Chemistry, 2014, 6, 2103-2112.	1.1	1
228	Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward. Future Medicinal Chemistry, 2014, 6, 1757-1769.	1.1	13
229	Increasing the Content of High-Content Screening: An Overview. Journal of Biomolecular Screening, 2014, 19, 640-650.	2.6	166
230	Active Learning Strategies for Phenotypic Profiling of High-Content Screens. Journal of Biomolecular Screening, 2014, 19, 685-695.	2.6	32
231	Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes. Molecular Therapy - Nucleic Acids, 2014, 3, e154.	2.3	40

#	Article	IF	CITATIONS
232	Extending <i>in silico</i> mechanism-of-action analysis by annotating targets with pathways: application to cellular cytotoxicity readouts. Future Medicinal Chemistry, 2014, 6, 2029-2056.	1.1	19
233	Regenerative Medicine: Transforming the Drug Discovery and Development Paradigm. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014084-a014084.	2.9	9
234	NMR screening of potential inhibitors of methionine $\hat{I}^3$ -lyase from Citrobacter freundii. Molecular Biology, 2014, 48, 896-905.	0.4	4
235	Automated, high-throughput, motility analysis in Caenorhabditis elegans and parasitic nematodes: Applications in the search for new anthelmintics. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 226-232.	1.4	61
236	Composition and applications of focus libraries to phenotypic assays. Frontiers in Pharmacology, 2014, 5, 164.	1.6	36
237	Epigenetic control of gene function in schistosomes: a source of therapeutic targets?. Frontiers in Genetics, 2014, 5, 317.	1.1	34
238	Natural products against cancer: A comprehensive bibliometric study of the research projects, publications, patents and drugs. Journal of Cancer Research and Therapeutics, 2014, 10, 27.	0.3	26
239	Engaging novel cell types, protein targets and efficacy biomarkers in the treatment of diabetic nephropathy. Frontiers in Pharmacology, 2014, 5, 185.	1.6	1
240	Assay Suitability for Natural Product Screening: Searching for Leads to Fight Alzheimer's Disease. Planta Medica, 2014, 80, 1200-1209.	0.7	4
241	The value of translational biomarkers to phenotypic assays. Frontiers in Pharmacology, 2014, 5, 171.	1.6	19
242	Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae. Molecular BioSystems, 2014, 10, 3179-3187.	2.9	18
243	Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Review of Molecular Diagnostics, 2014, 14, 153-168.	1.5	24
244	The discovery of medicines for rare diseases. Future Medicinal Chemistry, 2014, 6, 987-1002.	1.1	22
245	Potential strategies for increasing drug-discovery productivity. Future Medicinal Chemistry, 2014, 6, 515-527.	1.1	18
247	A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation. Nature Chemical Biology, 2014, 10, 1055-1060.	3.9	99
248	In Vivo Phenotypic Screening for Treating Chronic Neuropathic Pain: Modification of <i>C</i> >2-Arylethynyl Group of Conformationally Constrained A <sub>3</sub> Adenosine Receptor Agonists. Journal of Medicinal Chemistry, 2014, 57, 9901-9914.	2.9	48
249	Recent advances in technologies for developing drugs againstChlamydia pneumoniae. Expert Opinion on Drug Discovery, 2014, 9, 791-802.	2.5	7
250	Chapter 5. Complex Primary Human Cell Systems for Drug Discovery. RSC Drug Discovery Series, 2014, , 88-109.	0.2	1

#	Article	IF	CITATIONS
251	Chapter 8. Utility of Human Stem Cells for Drug Discovery. RSC Drug Discovery Series, 2014, , 162-193.	0.2	2
252	( <i>&gt;S</i> )-1-(Pent-4′-enoyl)-4-(hydroxymethyl)-azetidin-2-one derivatives as inhibitors of human fatty acid amide hydrolase ( <i>h</i> FAAH): synthesis, biological evaluation and molecular modelling. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 654-662.	2.5	1
253	Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report. Molecular and Cellular Proteomics, 2014, 13, 1625-1643.	2.5	152
254	Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses. Journal of Biomolecular Screening, 2014, 19, 771-781.	2.6	37
255	Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery. Journal of Biomolecular Screening, 2014, 19, 17-31.	2.6	43
256	Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection. Expert Opinion on Therapeutic Targets, 2014, 18, 1253-1264.	1.5	3
257	Building an Integrated Early Clinical Development Platform to Improve the Path to Proof of Concept. Therapeutic Innovation and Regulatory Science, 2014, 48, 546-551.	0.8	0
258	Molecular simulation of drug-binding kinetics. Molecular Simulation, 2014, 40, 889-903.	0.9	9
259	Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs. Journal of Law, Medicine and Ethics, 2014, 42, 564-575.	0.4	9
260	Spectinamides: a challenge, a proof, and a suggestion. Trends in Microbiology, 2014, 22, 170-171.	3.5	6
261	Plant extracts in cell-based anti-inflammatory assaysâ€"Pitfalls and considerations related to removal of activity masking bulk components. Phytochemistry Letters, 2014, 10, xli-xlvii.	0.6	6
262	Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discovery Today, 2014, 19, 171-182.	3.2	140
263	Engineering Xenopus embryos for phenotypic drug discovery screening. Advanced Drug Delivery Reviews, 2014, 69-70, 225-246.	6.6	55
264	The conformational musings of a medicinal chemist. Drug Discovery Today, 2014, 19, 320-325.	3.2	8
265	Novel Pyrrolidine Diketopiperazines Selectively Inhibit Melanoma Cells via Induction of Late-Onset Apoptosis. Journal of Medicinal Chemistry, 2014, 57, 1599-1608.	2.9	6
266	P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chemical Society Reviews, 2014, 43, 6716-6726.	18.7	85
267	Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?. Bone, 2014, 62, 56-63.	1.4	166
268	Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks. Journal of Biomolecular Screening, 2014, 19, 782-790.	2.6	23

#	Article	IF	CITATIONS
269	Systems biology in drug discovery and development. Drug Discovery Today, 2014, 19, 113-125.	3.2	80
270	Deducing the mechanism of action of compounds identified in phenotypic screens by integrating their multiparametric profiles with a reference genetic screen. Nature Protocols, 2014, 9, 474-490.	5.5	23
271	Driving Glioblastoma to Drink. Cell, 2014, 157, 289-290.	13.5	9
272	Developments in preclinical cancer imaging: innovating the discovery of therapeutics. Nature Reviews Cancer, 2014, 14, 314-328.	12.8	134
274	Development of tag-free photoprobes for studies aimed at identifying the target of novel Group A Streptococcus antivirulence agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1538-1544.	1.0	9
275	Synthesis of Complex and Diverse Compounds through Ring Distortion of Abietic Acid. Angewandte Chemie - International Edition, 2014, 53, 220-224.	7.2	110
276	Investigating and Predicting how Biology Changes Molecules and Their Properties. Molecular Informatics, 2014, 33, 443-445.	1.4	4
277	Drugâ€Target Residence Timeâ€"A Case for G Proteinâ€Coupled Receptors. Medicinal Research Reviews, 2014, 34, 856-892.	5.0	145
278	Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1643-1672.	2.9	68
280	Drug discovery through stem cell-based organoid models. Advanced Drug Delivery Reviews, 2014, 69-70, 19-28.	6.6	172
281	Drug Repositioning: Playing Dirty to Kill Pain. CNS Drugs, 2014, 28, 45-61.	2.7	34
282	Systems biology, complexity, and the impact on antiepileptic drug discovery. Epilepsy and Behavior, 2014, 38, 131-142.	0.9	34
283	Diversity-oriented synthesis as a tool for identifying new modulators of mitosis. Nature Communications, 2014, 5, 3155.	5.8	73
284	Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. Nature Chemical Biology, 2014, 10, 113-121.	3.9	110
285	Data-driven medicinal chemistry in the era of big data. Drug Discovery Today, 2014, 19, 859-868.	3.2	126
286	Translational paradigms in pharmacology and drug discovery. Biochemical Pharmacology, 2014, 87, 189-210.	2.0	31
287	Phenotypic Screens Targeting Neurodegenerative Diseases. Journal of Biomolecular Screening, 2014, 19, 1-16.	2.6	26
288	Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation, and Cell Cycle: Role and Targeting. Molecular Pharmacology, 2014, 85, 345-356.	1.0	73

#	Article	IF	CITATIONS
289	Overcoming the Challenges of Drug Discovery for Neglected Tropical Diseases: The A·WOL Experience. Journal of Biomolecular Screening, 2014, 19, 335-343.	2.6	40
290	Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. Advanced Drug Delivery Reviews, 2014, 69-70, 170-178.	6.6	25
291	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. Journal of Pharmaceutical Sciences, 2014, 103, 3377-3397.	1.6	60
292	Toxins and drug discovery. Toxicon, 2014, 92, 193-200.	0.8	156
293	A novel approach applying a chemical biology strategy in phenotypic screening reveals pathway-selective regulators of histone 3 K27 tri-methylation. Molecular BioSystems, 2014, 10, 251-257.	2.9	12
294	Chemical biology for target identification and validation. MedChemComm, 2014, 5, 244-246.	3.5	7
295	Phenotypic Profiling of Raf Inhibitors and Mitochondrial Toxicity in 3D Tissue Using Biodynamic Imaging. Journal of Biomolecular Screening, 2014, 19, 526-537.	2.6	28
296	The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development. Clinical Pharmacology and Therapeutics, 2014, 95, 521-527.	2.3	16
297	Combating neurodegenerative disease with chemical probes and model systems. Nature Chemical Biology, 2014, 10, 911-920.	3.9	43
298	In pursuit of the ideal antifungal agent for Candida infections: high-throughput screening of small molecules. Drug Discovery Today, 2014, 19, 1721-1730.	3.2	54
299	The Chemistry-Biology-Medicine Continuum and the Drug Discovery and Development Process in Academia. Chemistry and Biology, 2014, 21, 1039-1045.	6.2	19
300	Unbinding free energy of acetylcholinesterase bound oxime drugs along the gorge pathway from metadynamics-umbrella sampling investigation. Proteins: Structure, Function and Bioinformatics, 2014, 82, 1799-1818.	1.5	16
301	From yeast to patient neurons and back again: Powerful new discovery platforms. Movement Disorders, 2014, 29, 1231-1240.	2.2	28
302	A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14882-14887.	3.3	18
303	Chemical biology approaches to target validation in cancer. Current Opinion in Pharmacology, 2014, 17, 87-100.	1.7	36
304	Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning. Expert Opinion on Drug Discovery, 2014, 9, 1265-1279.	2.5	1
305	Mapping the Protein Interaction Landscape for Fully Functionalized Small-Molecule Probes in Human Cells. Journal of the American Chemical Society, 2014, 136, 10777-10782.	6.6	90
306	Induced Pluripotent Stem Cells for the Study of Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 64, 512-519.	1.2	40

#	Article	IF	CITATIONS
307	High-Throughput Screening Normalized to Biological Response: Application to Antiviral Drug Discovery. Journal of Biomolecular Screening, 2014, 19, 119-130.	2.6	16
308	Biological Networks and Drug Discovery—Where Do We Stand?. Drug Development Research, 2014, 75, 271-282.	1.4	12
310	A Screening Pattern Recognition Method Finds New and Divergent Targets for Drugs and Natural Products. ACS Chemical Biology, 2014, 9, 1622-1631.	1.6	34
311	Enrichment Analysis for Discovering Biological Associations in Phenotypic Screens. Journal of Chemical Information and Modeling, 2014, 54, 377-386.	2.5	12
312	Systems Biology Brings New Dimensions for Structure-Based Drug Design. Journal of the American Chemical Society, 2014, 136, 11556-11565.	6.6	75
313	The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens. Journal of Biomolecular Screening, 2014, 19, 696-706.	2.6	12
314	High Content Screening of Diverse Compound Libraries Identifies Potent Modulators of Tubulin Dynamics. ACS Medicinal Chemistry Letters, 2014, 5, 598-603.	1.3	15
315	Target Selection and Validation in Drug Discovery. Topics in Medicinal Chemistry, 2014, , 1-72.	0.4	0
316	Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites. Chemical Reviews, 2014, 114, 11280-11304.	23.0	55
317	Privileged Structures: Efficient Chemical "Navigators―toward Unexplored Biologically Relevant Chemical Spaces. Journal of the American Chemical Society, 2014, 136, 14629-14638.	6.6	242
318	Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery. Pharmaceutical Research, 2014, 31, 2203-2219.	1.7	55
319	The discovery of first-in-class drugs: origins and evolution. Nature Reviews Drug Discovery, 2014, 13, 577-587.	21.5	412
320	Phenotypic screening in cancer drug discovery â€" past, present and future. Nature Reviews Drug Discovery, 2014, 13, 588-602.	21.5	403
321	Evolving BioAssay Ontology (BAO): modularization, integration and applications. Journal of Biomedical Semantics, 2014, 5, S5.	0.9	75
322	From Catalytic Mechanism to Rational Design of Reversible Covalent Inhibitors of Serine and Cysteine Hydrolases. Israel Journal of Chemistry, 2014, 54, 1137-1151.	1.0	11
323	Molecular biodiversity and recent analytical developments: A marriage of convenience. Biotechnology Advances, 2014, 32, 1102-1110.	6.0	17
326	Balancing novelty with confined chemical space in modern drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 151-165.	2.5	47
327	Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect. Journal of Medicinal Chemistry, 2014, 57, 5057-5071.	2.9	96

#	Article	IF	CITATIONS
328	Can stem-cell-derived models revolutionize drug discovery?. Expert Opinion on Drug Discovery, 2014, 9, 9-13.	2.5	6
329	Recent Approaches to Chemical Discovery and Development Against Malaria and the Neglected Tropical Diseases Human African Trypanosomiasis and Schistosomiasis. Chemical Reviews, 2014, 114, 11138-11163.	23.0	91
330	Chemoproteomics Reveals Time-Dependent Binding of Histone Deacetylase Inhibitors to Endogenous Repressor Complexes. ACS Chemical Biology, 2014, 9, 1736-1746.	1.6	52
331	Metaphors in Nanomedicine: The Case of Targeted Drug Delivery. NanoEthics, 2014, 8, 1-17.	0.5	27
332	7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells. Tumor Biology, 2014, 35, 6983-6997.	0.8	13
333	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
334	Back to the Future with Phenotypic Screening. ACS Chemical Neuroscience, 2014, 5, 503-513.	1.7	91
335	The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential. Expert Opinion on Drug Discovery, 2014, 9, 847-858.	2.5	11
336	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds. Bioorganic and Medicinal Chemistry, 2014, 22, 5241-5248.	1.4	10
337	The Use of Antibodies in Small-Molecule Drug Discovery. Journal of Biomolecular Screening, 2014, 19, 829-838.	2.6	12
338	Biological Image Indexing for Content-Based Retrieval of Drug Effects in Phenotypic Screening Data of Macroparasites. , 2014, , .		0
339	Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types. Journal of Biological Chemistry, 2014, 289, 4562-4570.	1.6	37
340	Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discovery Today, 2014, 19, 637-644.	3.2	333
341	Consideration of the cellular microenvironment: Physiologically relevant co-culture systems in drug discovery. Advanced Drug Delivery Reviews, 2014, 69-70, 190-204.	6.6	43
342	Optimization of ketone-based P2Y12 receptor antagonists as antithrombotic agents: Pharmacodynamics and receptor kinetics considerations. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2963-2968.	1.0	8
343	Synthesis and evaluation of effective photoaffinity probe molecule of furospinosulin-1, a hypoxia-selective growth inhibitor. Bioorganic and Medicinal Chemistry, 2014, 22, 2102-2112.	1.4	11
344	A new method for filtering of reactive "warheads―of transition-state analog protease inhibitors. European Journal of Medicinal Chemistry, 2014, 77, 134-138.	2.6	4
345	Determining Physical Principles of Subcellular Organization. Developmental Cell, 2014, 29, 135-138.	3.1	14

#	Article	IF	CITATIONS
346	Label-free cell phenotypic profiling identifies pharmacologically active compounds in two traditional Chinese medicinal plants. RSC Advances, 2014, 4, 26368-26377.	1.7	24
347	Affinity-based target identification for bioactive small molecules. MedChemComm, 2014, 5, 277-287.	3.5	64
348	Functional binding assays for estimation of the intrinsic efficacy of ligands at the 5-HT1A receptor: Application for screening drug candidates. Journal of Pharmacological and Toxicological Methods, 2014, 70, 12-18.	0.3	11
349	Cancer wars: natural products strike back. Frontiers in Chemistry, 2014, 2, 20.	1.8	100
350	High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses. Journal of Visualized Experiments, 2014, , .	0.2	12
351	Early State Research on Antifungal Natural Products. Molecules, 2014, 19, 2925-2956.	1.7	74
352	Genetic Strategies for Identifying New Drug Targets. Microbiology Spectrum, 2014, 2, MGM2-0030-2013.	1.2	5
354	Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?. Journal of Traditional and Complementary Medicine, 2014, 4, 1-7.	1.5	56
357	Discovery of Inhibitors of <i>Trypanosoma brucei</i> by Phenotypic Screening of a Focused Protein Kinase Library. ChemMedChem, 2015, 10, 1809-1820.	1.6	15
362	3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells. Bioscience Reports, 2015, 35, .	1.1	92
363	The transporter-mediated cellular uptake of pharmaceutical drugs is based on their metabolite-likeness and not on their bulk biophysical properties: Towards a systems pharmacology. Perspectives in Science, 2015, 6, 66-83.	0.6	18
364	Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. , 2015, 3, 27.		17
365	Predicting target proteins for drug candidate compounds based on drug-induced gene expression data in a chemical structure-independent manner. BMC Medical Genomics, 2015, 8, 82.	0.7	35
366	ldentification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling. Molecular Cancer, 2015, 14, 147.	7.9	49
368	Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?1. Journal of Alzheimer's Disease, 2015, 47, 815-843.	1.2	84
369	å®ç"¶ç‰©ã«é©ã⊷ãŸãf•ã,SãfŽãf†ã,£ãf"ãffã,¯ã,¹ã,¯ãfªãf¼ãf‹ãf³ã,°. Kagaku To Seibutsu, 2015, 54, 32-36.	0.0	0
370	Title is missing!. Kagaku To Seibutsu, 2015, 54, 43-47.	0.0	0
371	Elucidation of direct competition and allosteric modulation of small-molecular-weight protein ligands using surface plasmon resonance methods. Journal of Molecular Recognition, 2015, 28, 480-491.	1.1	3

#	ARTICLE	IF	CITATIONS
372	Colorectal cancer drug target prediction using ontology-based inference and network analysis. Database: the Journal of Biological Databases and Curation, 2015, 2015, .	1.4	28
373	Meyer controlled Watershed segmentation on Schistosomiasis in HyperSpectral data analysis., 2015,,.		2
374	Unconventional screening approaches for antibiotic discovery. Annals of the New York Academy of Sciences, 2015, 1354, 54-66.	1.8	46
375	Novel Synthetic Pharmacophores Inducing a Stabilization of Cellular Microtubules. Current Cancer Drug Targets, 2015, 15, 2-13.	0.8	4
376	A Quantitative Systems Pharmacology Perspective on Cancer Immunology. Processes, 2015, 3, 235-256.	1.3	8
377	Enhancement of Cortical Network Activity in vitro and Promotion of GABAergic Neurogenesis by Stimulation with an Electromagnetic Field with a 150 MHz Carrier Wave Pulsed with an Alternating 10 and 16 Hz Modulation. Frontiers in Neurology, 2015, 6, 158.	1.1	16
378	Explicit Drug Re-positioning. Advances in Protein Chemistry and Structural Biology, 2015, 100, 89-112.	1.0	4
379	Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery. PLoS Neglected Tropical Diseases, 2015, 9, e0003878.	1.3	74
380	Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays. PLoS ONE, 2015, 10, e0130796.	1.1	18
381	Considerations for designing chemical screening strategies in plant biology. Frontiers in Plant Science, 2015, 6, 131.	1.7	36
382	Overcome Cancer Cell Drug Resistance Using Natural Products. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-14.	0.5	61
383	A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver. ELife, 2015, 4, .	2.8	35
385	Will Understanding Methotrexate Modes of Action Teach us About Rheumatoid Arthritis?., 0,,.		0
386	Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2015, 6, 618-621.	1.3	24
387	Core-shell hydrogel beads with extracellular matrix for tumor spheroid formation. Biomicrofluidics, 2015, 9, 024118.	1.2	30
388	Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. Journal of the American Chemical Society, 2015, 137, 7929-7934.	6.6	29
389	High-throughput screening for modulators of cellular contractile force. Integrative Biology (United) Tj ETQq0 0 (	) rgBT/Ove	erlock 10 Tf 50
390	MicroRNA Therapeutics in Cardiovascular Disease. , 2015, , 253-263.		3

#	Article	IF	Citations
391	The Life Sciences Translational Challenge: The European Perspective. Therapeutic Innovation and Regulatory Science, 2015, 49, 415-424.	0.8	2
392	Linking Phenotypes and Modes of Action Through High-Content Screen Fingerprints. Assay and Drug Development Technologies, 2015, 13, 415-427.	0.6	67
393	Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases. Chemistry Central Journal, 2015, 9, 65.	2.6	98
394	A high-throughput assay for quantifying appetite and digestive dynamics. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R345-R357.	0.9	24
395	Luteolin acts as a radiosensitizer in non-small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade. International Journal of Oncology, 2015, 46, 1149-1158.	1.4	49
396	Small Molecules Detected by Second-Harmonic Generation Modulate the Conformation of Monomeric α-Synuclein and Reduce Its Aggregation in Cells. Journal of Biological Chemistry, 2015, 290, 27582-27593.	1.6	53
397	Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease. Neurotherapeutics, 2015, 12, 132-142.	2.1	58
398	Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology, 2015, 25, 599-656.	0.3	113
399	Cell-Based Assays for Neurotoxins. Toxinology, 2015, , 247-271.	0.2	3
400	DrugNet: Network-based drug–disease prioritization by integrating heterogeneous data. Artificial Intelligence in Medicine, 2015, 63, 41-49.	3.8	175
401	High-throughput analysis of behavior for drug discovery. European Journal of Pharmacology, 2015, 750, 82-89.	1.7	58
402	Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Reports, 2015, 10, 755-770.	2.9	21
403	Surviving the gauntlet: Modern challenges in cardiovascular drug approval and implementation. American Heart Journal, 2015, 169, 191-193.	1.2	0
404	Novel Therapeutic Approaches for Neglected Infectious Diseases. Journal of Biomolecular Screening, 2015, 20, 3-5.	2.6	8
405	Targetâ€Based Wholeâ€Cell Screening by <sup>1</sup> Hâ€NMR Spectroscopy. Angewandte Chemie - International Edition, 2015, 54, 4764-4767.	7.2	20
406	Antitumor activity of an antiâ€ <scp>CD</scp> 98 antibody. International Journal of Cancer, 2015, 137, 710-720.	2.3	51
407	Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Research, 2015, 110, 189-205.	0.8	163
408	An Ancient Riboswitch Class in Bacteria Regulates Purine Biosynthesis and One-Carbon Metabolism. Molecular Cell, 2015, 57, 317-328.	4.5	102

#	Article	IF	CITATIONS
410	Constellation Pharmacology: A New Paradigm for Drug Discovery. Annual Review of Pharmacology and Toxicology, 2015, 55, 573-589.	4.2	37
411	Nonconventional chemical inhibitors of microRNA: therapeutic scope. Chemical Communications, 2015, 51, 820-831.	2.2	30
412	Addressing the Right Targets in Oncology. Journal of Biomolecular Screening, 2015, 20, 305-317.	2.6	14
414	Discovery and optimization of novel dual dithiocarbamates as potent anticancer agents. European Journal of Medicinal Chemistry, 2015, 93, 381-391.	2.6	45
415	High-Content Screening Applied to Nervous System Injury. , 2015, , 411-419.		0
416	Genetic Approaches to Facilitate Antibacterial Drug Development. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021139.	2.9	15
417	Reprint of: Highthroughtput analysis of behavior for drug discovery. European Journal of Pharmacology, 2015, 753, 127-134.	1.7	7
418	Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity. Clinical Therapeutics, 2015, 37, 1643-1651.e3.	1.1	14
419	Molecular mechanism matters: Benefits of mechanistic computational models for drug development. Pharmacological Research, 2015, 99, 149-154.	3.1	30
420	Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide â€" Amide derivatives of valproic acid. Epilepsy and Behavior, 2015, 46, 72-78.	0.9	9
421	4-Fluoro-3′,4′,5′-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an inÂvivo metastasis model. European Journal of Medicinal Chemistry, 2015, 101, 627-639.	2.6	13
422	Galactosylated magnetic nanovectors for regulation of lipid metabolism based on biomarker-specific RNAi and MR imaging. Nanotechnology, 2015, 26, 335101.	1.3	1
423	Evaluation of the Biological Activity of Compounds. , 2015, , 15-43.		10
424	Drug Targets, Target Identification, Validation, and Screening. , 2015, , 45-70.		2
425	Strategies in the Search for New Lead Compounds or Original Working Hypotheses., 2015,, 73-99.		15
426	Natural Products as Pharmaceuticals and Sources for Lead Structures**Note: This chapter reflects the opinions of the authors, not necessarily those of the US Government., 2015, , 101-139.		13
427	Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator. Drug Discovery Today, 2015, 20, 1300-1304.	3.2	6
428	Academic drug discovery within the United Kingdom: a reassessment. Nature Reviews Drug Discovery, 2015, 14, 510-510.	21.5	22

#	Article	IF	Citations
429	Developing predictive assays: The phenotypic screening "rule of 3― Science Translational Medicine, 2015, 7, 293ps15.	5.8	153
430	Diverse display of non-covalent interacting elements using pyrimidine-embedded polyheterocycles. Chemical Communications, 2015, 51, 13040-13043.	2.2	6
431	On the â€~micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action. Expert Opinion on Drug Discovery, 2015, 10, 1085-1098.	2.5	37
432	Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class―anti-inflammatory drug candidates: a reviewer's perspective. Inflammation Research, 2015, 64, 747-752.	1.6	11
433	Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery. Archives of Pharmacal Research, 2015, 38, 1627-1641.	2.7	45
434	Do We Need a Science of Science?. , 2015, , 3-53.		0
435	Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. ACS Chemical Biology, 2015, 10, 1939-1951.	1.6	58
436	Cell-based and virtual fragment screening for adrenergic α2C receptor agonists. Bioorganic and Medicinal Chemistry, 2015, 23, 3991-3999.	1.4	11
437	Microwave Controlled Reductive Cyclization: A Selective Synthesis of Novel Benzimidazole-alkyloxypyrrolo[1,2- <i>a</i> ]quinoxalinones. ACS Combinatorial Science, 2015, 17, 310-316.	3.8	22
438	Application of cultured human mast cells (CHMC) for the design and structure–activity relationship of IgE-mediated mast cell activation inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2117-2121.	1.0	4
439	Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 1504-1516.	1.9	122
440	Alternative Reagents for Methotrexate as Immobilizing Anchor Moieties in the Optimization of MASPIT: Synthesis and Biological Evaluation. ChemBioChem, 2015, 16, 834-843.	1.3	5
441	Natural product extracts of the Canadian prairie plant, <i>Thermopsis rhombifolia, </i> have anti-cancer activity in phenotypic cell-based assays. Natural Product Research, 2015, 29, 1026-1034.	1.0	9
442	Future Translational Applications From the Contemporary Genomics Era. Circulation, 2015, 131, 1715-1736.	1.6	38
443	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 2015, 95, 29-34.	2.6	31
444	Zebrafish Models of Kidney Damage and Repair. Current Pathobiology Reports, 2015, 3, 163-170.	1.6	11
445	A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules. Journal of the American Society of Nephrology: JASN, 2015, 26, 2741-2752.	3.0	53
446	Fragment-Based Screening in Tandem with Phenotypic Screening Provides Novel Antiparasitic Hits. Journal of Biomolecular Screening, 2015, 20, 131-140.	2.6	23

#	Article	IF	Citations
447	An analysis of FDA-approved drugs for neurological disorders. Drug Discovery Today, 2015, 20, 1040-1043.	3.2	22
448	Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nature Reviews Neurology, 2015, 11, 339-350.	4.9	65
449	Privileged scaffolds in lead generation. Expert Opinion on Drug Discovery, 2015, 10, 781-790.	2.5	71
450	Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. Bioorganic and Medicinal Chemistry, 2015, 23, 5087-5097.	1.4	90
451	<i>In silico</i> tools used for compound selection during target-based drug discovery and development. Expert Opinion on Drug Discovery, 2015, 10, 901-923.	2.5	16
452	Phenotype-driven chemical screening in zebrafish for compounds that inhibit collective cell migration identifies multiple pathways potentially involved in metastatic invasion. DMM Disease Models and Mechanisms, 2015, 8, 565-576.	1.2	47
453	Combining label-free cell phenotypic profiling with computational approaches for novel drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 331-343.	2.5	19
454	Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 2015, 14, 248-260.	21.5	930
455	Flow Cytometry: Impact on Early Drug Discovery. Journal of Biomolecular Screening, 2015, 20, 689-707.	2.6	54
456	A High-Throughput Phenotypic Screen of Cytotoxic T Lymphocyte Lytic Granule Exocytosis Reveals Candidate Immunosuppressants. Journal of Biomolecular Screening, 2015, 20, 359-371.	2.6	13
457	High-throughput fluorescence imaging approaches for drug discovery using <i>in vitro </i> vivo  three-dimensional models. Expert Opinion on Drug Discovery, 2015, 10, 1347-1361.	2.5	47
458	CETSA: a target engagement assay with potential to transform drug discovery. Future Medicinal Chemistry, 2015, 7, 975-978.	1.1	40
459	The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review. Handbook of Experimental Pharmacology, 2015, 231, 95-128.	0.9	38
460	Selective small-molecule inhibition of an RNA structural element. Nature, 2015, 526, 672-677.	13.7	339
461	The problem of genotype and sex differences in life expectancy in transgenic AD mice. Neuroscience and Biobehavioral Reviews, 2015, 57, 238-251.	2.9	68
462	An abietane diterpene from Salvia cuspidata and some new derivatives are active against Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5481-5484.	1.0	16
463	Recent developments and applications of clickable photoprobes in medicinal chemistry and chemical biology. Future Medicinal Chemistry, 2015, 7, 2143-2171.	1.1	52
464	Chemical genetics and regeneration. Future Medicinal Chemistry, 2015, 7, 2263-2283.	1.1	4

#	Article	IF	CITATIONS
465	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature Chemical Biology, 2015, 11, 973-980.	3.9	114
466	Whole-genome sequencing targets drug-resistant bacterial infections. Human Genomics, 2015, 9, 19.	1.4	86
467	Equisetin, reutericyclin and streptolodygin as natural product lead structures for novel antibiotic libraries. Future Medicinal Chemistry, 2015, 7, 1861-1877.	1.1	6
468	Unknown unknowns in biomedical research: does an inability to deal with ambiguity contribute to issues of irreproducibility?. Biochemical Pharmacology, 2015, 97, 133-136.	2.0	35
469	Affinity purification in target identification: the specificity challenge. Archives of Pharmacal Research, 2015, 38, 1661-1685.	2.7	24
470	Deciphering the Cellular Targets of Bioactive Compounds Using a Chloroalkane Capture Tag. ACS Chemical Biology, 2015, 10, 2316-2324.	1.6	36
471	Phenotypic Assays to Identify Agents That Induce Reactive Gliosis: A Counter-Screen to Prioritize Compounds for Preclinical Animal Studies. Assay and Drug Development Technologies, 2015, 13, 377-388.	0.6	9
472	Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnology Advances, 2015, 33, 1582-1614.	6.0	1,871
473	Discovery of new targets of phenolic acids in danshen using a label-free cell phenotypic assay. RSC Advances, 2015, 5, 25768-25776.	1.7	6
474	A Combination of Screening and Computational Approaches for the Identification of Novel Compounds That Decrease Mast Cell Degranulation. Journal of Biomolecular Screening, 2015, 20, 720-728.	2.6	7
475	Zebrafish as tools for drug discovery. Nature Reviews Drug Discovery, 2015, 14, 721-731.	21.5	888
476	Validation of Miniaturized One-Step Reverse Transcription qPCR Assays for High-Throughput Screening and Comparison to a Reporter Gene Methodology. Assay and Drug Development Technologies, 2015, 13, 94-101.	0.6	5
477	Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nature Reviews Drug Discovery, 2015, 14, 693-720.	21.5	181
478	Are label-free investigations the best approach to drug discovery?. Future Medicinal Chemistry, 2015, 7, 1561-1564.	1.1	10
479	Radioligand binding to intact cells as a tool for extended drug screening in a representative physiological context. Drug Discovery Today: Technologies, 2015, 17, 28-34.	4.0	12
480	Functional genomics to uncover drug mechanism of action. Nature Chemical Biology, 2015, 11, 942-948.	3.9	70
481	Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials. ACS Chemical Biology, 2015, 10, 413-420.	1.6	75
482	The pharmaceutical industry and natural products: historical status and new trends. Phytochemistry Reviews, 2015, 14, 299-315.	3.1	375

#	Article	IF	CITATIONS
483	Biologically active compounds based on the privileged 2-imidazoline scaffold: The world beyond adrenergic/imidazoline receptor modulators. European Journal of Medicinal Chemistry, 2015, 97, 525-537.	2.6	45
484	The opportunities of mining historical and collective data in drug discovery. Drug Discovery Today, 2015, 20, 422-434.	3.2	27
485	15 years of zebrafish chemical screening. Current Opinion in Chemical Biology, 2015, 24, 58-70.	2.8	239
486	High-Content Phenotypic Screening and Triaging Strategy to Identify Small Molecules Driving Oligodendrocyte Progenitor Cell Differentiation. Journal of Biomolecular Screening, 2015, 20, 382-390.	2.6	16
487	An analysis of FDA-approved drugs for psychiatric disorders. Drug Discovery Today, 2015, 20, 292-295.	3.2	5
488	Cell-Based Assay Design for High-Content Screening of Drug Candidates. Journal of Microbiology and Biotechnology, 2016, 26, 213-225.	0.9	72
489	Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 272-321.	0.9	214
490	Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines. Journal of Immunology Research, 2016, 2016, 1-9.	0.9	32
491	Prediscovery Research: Challenges and Opportunities. , 2016, , 85-108.		0
492	Application of Omics Technologies for Evaluation of Antibacterial Mechanisms of Action of Plant-Derived Products. Frontiers in Microbiology, 2016, 7, 1466.	1.5	44
493	Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. Biomedicines, 2016, 4, 27.	1.4	23
494	Translational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug Discovery. Cells, 2016, 5, 46.	1.8	21
495	Systems Pharmacology in Small Molecular Drug Discovery. International Journal of Molecular Sciences, 2016, 17, 246.	1.8	101
496	Protein-Directed Dynamic Combinatorial Chemistry: A Guide to Protein Ligand and Inhibitor Discovery. Molecules, 2016, 21, 910.	1.7	34
497	Resurrection of neurodegenerative diseases via stem cells. Biomedical Research and Therapy, 2016, 3, .	0.3	0
498	Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni. PLoS Neglected Tropical Diseases, 2016, 10, e0004356.	1.3	56
499	A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β. PLoS Neglected Tropical Diseases, 2016, 10, e0004506.	1.3	17
500	Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis. Journal of Cancer, 2016, 7, 192-199.	1.2	29

#	Article	IF	CITATIONS
501	Opportunities and Challenges for Drug Development: Publicâ€"Private Partnerships, Adaptive Designs and Big Data. Frontiers in Pharmacology, 2016, 7, 461.	1.6	60
502	Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies. Brazilian Journal of Medical and Biological Research, 2016, 49, e5644.	0.7	55
503	Defining desirable natural product derived anticancer drug space: optimization of molecular physicochemical properties and ADMET attributes. ADMET and DMPK, 2016, 4, 98.	1.1	12
505	Chemical Dimerizers in Three-Hybrid Systems for Small Molecule–Target Protein Profiling. ACS Chemical Biology, 2016, 11, 2075-2090.	1.6	4
506	Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery. Angewandte Chemie - International Edition, 2016, 55, 7586-7605.	7.2	150
507	Glial cells as drug targets: What does it take?. Glia, 2016, 64, 1742-1754.	2.5	24
508	Comparative transcriptomic analysis identifies genes differentially expressed in human epicardial progenitors and hiPSC-derived cardiac progenitors. Physiological Genomics, 2016, 48, 771-784.	1.0	2
509	Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes. BMC Cancer, 2016, 16, 810.	1.1	20
510	ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2016, 11, 56.	4.4	26
511	Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections. Parasites and Vectors, 2016, 9, 376.	1.0	34
512	Drug Discovery in Fish, Flies, and Worms. ILAR Journal, 2016, 57, 133-143.	1.8	66
513	Computational approaches to drug target identification. , 0, , 17-46.		0
514	Understanding human disease knowledge through text mining., 0,, 47-62.		2
515	Drug targets prediction using chemical similarity. , 2016, , .		5
516	Computational methods for prediction of in vitro effects of new chemical structures. Journal of Cheminformatics, 2016, 8, 51.	2.8	58
517	Novel spiropyrazolone antitumor scaffold with potent activity: Design, synthesis and structure–activity relationship. European Journal of Medicinal Chemistry, 2016, 115, 141-147.	2.6	53
518	Academic–Industrial Collaboration: Toward the Consilience of Two Solitudes. ACS Medicinal Chemistry Letters, 2016, 7, 6-9.	1.3	7
519	Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury. American Journal of Physiology - Renal Physiology, 2016, 310, F705-F716.	1.3	28

#	Article	IF	CITATIONS
520	Drug combination therapy increases successful drug repositioning. Drug Discovery Today, 2016, 21, 1189-1195.	3.2	284
521	Novel approaches to map small molecule–target interactions. Bioorganic and Medicinal Chemistry, 2016, 24, 3232-3245.	1.4	20
522	Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns. MedChemComm, 2016, 7, 1237-1244.	3.5	18
523	The evolution of drug discovery: from phenotypes to targets, and back. MedChemComm, 2016, 7, 788-798.	3.5	31
524	Shutting down the pore: The search for small molecule inhibitors of the mitochondrial permeability transition. Biochimica Et Biophysica Acta - Bioenergetics, 2016, 1857, 1197-1202.	0.5	26
525	Future Directions in Pain Management. Mayo Clinic Proceedings, 2016, 91, 522-533.	1.4	10
526	Discovery of Enhancers of the Secretion of Leukemia Inhibitory Factor for the Treatment of Multiple Sclerosis. Journal of Biomolecular Screening, 2016, 21, 437-445.	2.6	10
527	<i>In vivo</i> phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents. MedChemComm, 2016, 7, 1093-1101.	3.5	10
528	The analysis of the market success of FDA approvals by probing top 100 bestselling drugs. Journal of Computer-Aided Molecular Design, 2016, 30, 381-389.	1.3	10
529	Advanced molecular dynamics simulation methods for kinase drug discovery. Future Medicinal Chemistry, 2016, 8, 545-566.	1.1	21
530	Applications in image-based profiling of perturbations. Current Opinion in Biotechnology, 2016, 39, 134-142.	3.3	133
531	Screening out irrelevant cell-based models of disease. Nature Reviews Drug Discovery, 2016, 15, 751-769.	21.5	402
532	BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells. Stem Cell Research, 2016, 17, 212-221.	0.3	38
533	Zebrafish small molecule screens: Taking the phenotypic plunge. Computational and Structural Biotechnology Journal, 2016, 14, 350-356.	1.9	24
534	Virtual Screening Applications in the Search of Novel Antiepileptic Drug Candidates. Methods in Pharmacology and Toxicology, 2016, , 237-258.	0.1	1
535	Network Pharmacology and Epilepsy. Methods in Pharmacology and Toxicology, 2016, , 351-364.	0.1	1
536	The Evolving Role of the Medicinal Chemist. Progress in Medicinal Chemistry, 2016, 55, 193-226.	4.1	3
537	Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5819-5824.	1.0	6

#	Article	IF	CITATIONS
538	Systematic Identification of Pharmacological Targets from Small-Molecule Phenotypic Screens. Cell Chemical Biology, 2016, 23, 1302-1313.	2.5	11
539	Increasing experimental reproducibility, from antibodies to protein arrays. Drug Discovery Today, 2016, 21, 1197-1199.	3.2	0
541	2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. Journal of Medicinal Chemistry, 2016, 59, 7311-7351.	2.9	35
542	Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models. ACS Chemical Neuroscience, 2016, 7, 1499-1507.	1.7	22
543	Cancer drug discovery: recent innovative approaches to tumor modeling. Expert Opinion on Drug Discovery, 2016, 11, 885-894.	2.5	23
544	Considerations of Protein Subpockets in Fragmentâ€Based Drug Design. Chemical Biology and Drug Design, 2016, 87, 5-20.	1.5	13
546	Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nature Protocols, 2016, 11, 1757-1774.	5.5	608
547	Identification of protein binding partners of small molecules using label-free methods. Expert Opinion on Drug Discovery, 2016, 11, 1017-1025.	2.5	20
548	In Vitro and in Vivo Anti-Trypanosoma cruziActivity of New Arylamine Mannich Base-Type Derivatives. Journal of Medicinal Chemistry, 2016, 59, 10929-10945.	2.9	30
549	Search for Anti-angiogenic Substances from Natural Sources. Chemical and Pharmaceutical Bulletin, 2016, 64, 128-134.	0.6	10
552	Phenotypic Screening of Small-Molecule Inhibitors: Implications for Therapeutic Discovery and Drug Target Development in Traumatic Brain Injury. Methods in Molecular Biology, 2016, 1462, 677-688.	0.4	5
553	Access to a Structurally Complex Compound Collection via Ring Distortion of the Alkaloid Sinomenine. Organic Letters, 2016, 18, 4852-4855.	2.4	50
554	Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases. Clinical Pharmacology and Therapeutics, 2016, 100, 339-341.	2.3	5
555	Next-generation phenotypic screening. Future Medicinal Chemistry, 2016, 8, 1331-1347.	1.1	39
556	Computational approaches for innovative antiepileptic drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 1001-1016.	2.5	13
559	ARQiv-HTS, a versatile whole-organism screening platform enabling in vivo drug discovery at high-throughput rates. Nature Protocols, 2016, 11, 2432-2453.	5.5	50
560	Zebrafish as an in vivo model for sustainable chemical design. Green Chemistry, 2016, 18, 6410-6430.	4.6	26
561	The Many Facets of Screening Library Design. ACS Symposium Series, 2016, , 345-364.	0.5	1

#	Article	IF	Citations
562	F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12809-12814.	3.3	187
563	Diversity-oriented synthetic strategy for developing a chemical modulator of protein–protein interaction. Nature Communications, 2016, 7, 13196.	5 <b>.</b> 8	45
564	Generation of a monoclonal antibody recognizing the CEACAM glycan structure and inhibiting adhesion using cancer tissue-originated spheroid as an antigen. Scientific Reports, 2016, 6, 24823.	1.6	10
565	Automated Protocol for Large-Scale Modeling of Gene Expression Data. Journal of Chemical Information and Modeling, 2016, 56, 2216-2224.	2.5	5
566	Principles of dynamical modularity in biological regulatory networks. Scientific Reports, 2016, 6, 21957.	1.6	33
567	Vitamin E $\hat{\Gamma}$ -tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells. Scientific Reports, 2016, 6, 30502.	1.6	56
569	Cu(I) catalyzed microwave assisted telescopic synthesis of 3,5-disubstituted isoxazoles in green media. Tetrahedron Letters, 2016, 57, 5514-5517.	0.7	29
570	Tubulin is a molecular target of the Wnt-activating chemical probe. BMC Biochemistry, 2016, 17, 9.	4.4	13
571	Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes. Proteome Science, 2016, 15, 13.	0.7	101
572	GerüstdiversitÃ <b>t</b> sbasierte Synthese und ihre Anwendung bei der Sonden―und Wirkstoffsuche. Angewandte Chemie, 2016, 128, 7712-7732.	1.6	33
574	Screening Microorganisms for Bioactive Compounds. , 2016, , 345-376.		1
575	Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 2016, 14, 105.	1.8	231
576	Systematic Targeting of Protein–Protein Interactions. Trends in Pharmacological Sciences, 2016, 37, 702-713.	4.0	142
577	The Future of Cardiovascular Therapeutics. Circulation, 2016, 133, 2610-2617.	1.6	22
578	Phenotypic Assessment and the Discovery of Topiramate. ACS Medicinal Chemistry Letters, 2016, 7, 662-665.	1.3	16
579	Underexplored Opportunities for Natural Products in Drug Discovery. Journal of Medicinal Chemistry, 2016, 59, 9295-9304.	2.9	94
580	The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery. Research Policy, 2016, 45, 1570-1585.	3.3	57
581	Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods, 2016, 81, 263-273.	0.3	31

#	Article	IF	CITATIONS
582	Advantages and Challenges of Phenotypic Screens: The Identification of Two Novel Antifungal Geranylgeranyltransferase I Inhibitors. Journal of Biomolecular Screening, 2016, 21, 306-315.	2.6	9
583	Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway. Journal of Biomolecular Screening, 2016, 21, 608-619.	2.6	31
584	Morphological Evaluation of Nonlabeled Cells to Detect Stimulation of Nerve Growth Factor Expression by Lyconadin B. Journal of Biomolecular Screening, 2016, 21, 795-803.	2.6	8
585	Inflammatory pathway network-based drug repositioning and molecular phenomics. Molecular BioSystems, 2016, 12, 2777-2784.	2.9	6
586	Vacuolinâ€1 inhibits autophagy by impairing lysosomal maturation via <scp>PIK</scp> fyve inhibition. FEBS Letters, 2016, 590, 1576-1585.	1.3	35
587	Materials Research for Manufacturing. Springer Series in Materials Science, 2016, , .	0.4	5
588	The discovery and characterization of a novel scaffold as a potent hepatitis C virus inhibitor. Chemical Communications, 2016, 52, 3340-3343.	2.2	9
589	Corning Incorporated: Designing a New Future with Glass and Optics. Springer Series in Materials Science, 2016, , 1-38.	0.4	3
590	Target identification by image analysis. Natural Product Reports, 2016, 33, 655-667.	5.2	31
591	Computer-Aided Drug Discovery Approaches against the Tropical Infectious Diseases Malaria, Tuberculosis, Trypanosomiasis, and Leishmaniasis. ACS Infectious Diseases, 2016, 2, 8-31.	1.8	48
592	Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nature Chemical Biology, 2016, 12, 102-108.	3.9	72
593	Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nature Chemical Biology, 2016, 12, 109-116.	3.9	636
594	Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts. Investigational New Drugs, 2016, 34, 24-40.	1.2	49
595	Practical and low cost whole-organism motility assay: A step-by-step protocol. Molecular and Cellular Probes, 2016, 30, 13-17.	0.9	30
596	The development of high-content screening (HCS) technology and its importance to drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 501-514.	2.5	39
597	Translatability: what does it mean in drug discovery?. Drug Discovery Today, 2016, 21, 865-867.	3.2	1
598	A Grand Challenge: Unbiased Phenotypic Function of Metabolites from <i>Jaspis splendens</i> against Parkinson's Disease. Journal of Natural Products, 2016, 79, 353-361.	1.5	19
599	Natural products-prompted chemical biology: phenotypic screening and a new platform for target identification. Natural Product Reports, 2016, 33, 648-654.	5.2	49

#	Article	IF	CITATIONS
600	Compound annotation with real time cellular activity profiles to improve drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 269-280.	2.5	3
601	Evolution of strategies to improve preclinical cardiac safety testing. Nature Reviews Drug Discovery, 2016, 15, 457-471.	21.5	323
602	Filtering promiscuous compounds in early drug discovery: is it a good idea?. Drug Discovery Today, 2016, 21, 868-872.	3.2	73
603	The first report on coagulation and phospholipase A2 activities of Persian Gulf lionfish, Pterois russelli, an Iranian venomous fish. Toxicon, 2016, 113, 25-31.	0.8	32
604	Repurposing Drugs to Target the Diabetes Epidemic. Trends in Pharmacological Sciences, 2016, 37, 379-389.	4.0	38
605	Discovery of neuroprotective compounds by machine learning approaches. RSC Advances, 2016, 6, 9857-9871.	1.7	27
606	Stimulated Raman scattering microscopy: an emerging tool for drug discovery. Chemical Society Reviews, 2016, 45, 2075-2089.	18.7	198
607	Statistical Methods for Drug Discovery. Statistics in the Health Sciences, 2016, , 53-81.	0.2	3
608	The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods. Cell Chemical Biology, 2016, 23, 3-9.	2.5	97
609	Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmology, 2016, 16, 11.	0.6	34
610	A Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced Apoptosis. ACS Chemical Biology, 2016, 11, 1428-1437.	1.6	16
611	Recent advances in quantitative high throughput and high content data analysis. Expert Opinion on Drug Discovery, 2016, 11, 415-423.	2.5	7
612	Behavioral Analysis of Dopaminergic Activation in Zebrafish and Rats Reveals Similar Phenotypes. ACS Chemical Neuroscience, 2016, 7, 633-646.	1.7	46
613	Threading the Needle: Small-Molecule Targeting of a Xenobiotic Receptor to Ablate <i>Escherichia coli</i> Polysaccharide Capsule Expression Without Altering Antibiotic Resistance. Journal of Infectious Diseases, 2016, 213, 1330-1339.	1.9	14
614	Convertible visceral fat as a therapeutic target to curb obesity. Nature Reviews Drug Discovery, 2016, 15, 405-424.	21.5	177
615	Novel drug discovery for Chagas disease. Expert Opinion on Drug Discovery, 2016, 11, 447-455.	2.5	18
616	One size does not fit all: Challenging some dogmas and taboos in drug discovery. Future Medicinal Chemistry, 2016, 8, 29-38.	1.1	15
617	The resurgence of phenotypic screening in drug discovery and development. Expert Opinion on Drug Discovery, 2016, 11, 121-125.	2.5	44

#	Article	IF	Citations
618	Natural product discovery: past, present, and future. Journal of Industrial Microbiology and Biotechnology, 2016, 43, 155-176.	1.4	738
619	Discrimination between conformational selection and induced fit protein–ligand binding using Integrated Global Fit analysis. European Biophysics Journal, 2016, 45, 245-257.	1.2	15
620	Comparisons of cell culture medium using distribution of morphological features in microdevice. Journal of Bioscience and Bioengineering, 2016, 121, 117-123.	1.1	7
621	High-throughput imaging: Focusing in on drug discovery in 3D. Methods, 2016, 96, 97-102.	1.9	95
622	In silico assessment of adverse drug reactions and associated mechanisms. Drug Discovery Today, 2016, 21, 58-71.	3.2	51
623	A new paradigm for navigating compound property related drug attrition. Drug Discovery Today, 2016, 21, 72-81.	<b>3.</b> 2	41
624	Anticancer metallohelices: nanomolar potency and high selectivity. Chemical Science, 2016, 7, 951-958.	3.7	53
625	Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases. Annual Review of Pharmacology and Toxicology, 2016, 56, 489-510.	4.2	72
626	Investigation of Specific Binding Proteins to Photoaffinity Linkers for Efficient Deconvolution of Target Protein. ACS Chemical Biology, 2016, 11, 44-52.	1.6	59
627	Discovery of novel drug targets and their functions using phenotypic screening of natural products. Journal of Industrial Microbiology and Biotechnology, 2016, 43, 221-231.	1.4	21
628	Why and how have drug discovery strategies in pharma changed? What are the new mindsets?. Drug Discovery Today, 2016, 21, 239-249.	3.2	62
629	The Fox and the Hedgehog: A Vision of Neuroscience Research in Psychiatry. Academic Psychiatry, 2016, 40, 555-557.	0.4	0
630	Natural products as probes in pharmaceutical research. Journal of Industrial Microbiology and Biotechnology, 2016, 43, 249-260.	1.4	18
631	Phenotypic screening: the future of antibody discovery. Drug Discovery Today, 2016, 21, 150-156.	3.2	17
632	Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods. Pharmaceutical Research, 2016, 33, 194-205.	1.7	20
633	Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. Journal of Medicinal Chemistry, 2016, 59, 2-15.	2.9	31
634	Identifying compound efficacy targets in phenotypic drug discovery. Drug Discovery Today, 2016, 21, 82-89.	3.2	127
635	Orphan diseases: state of the drug discovery art. Wiener Medizinische Wochenschrift, 2017, 167, 197-204.	0.5	8

#	Article	IF	CITATIONS
636	Studying human disease using human neurons. Brain Research, 2017, 1656, 40-48.	1.1	21
637	Ligand and Target Discovery by Fragment-Based Screening in Human Cells. Cell, 2017, 168, 527-541.e29.	13.5	330
638	In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery. ACS Chemical Neuroscience, 2017, 8, 785-797.	1.7	10
639	Validation of a Na + -shift binding assay for estimation of the intrinsic efficacy of ligands at the A 2A adenosine receptor. Journal of Pharmacological and Toxicological Methods, 2017, 84, 51-56.	0.3	6
640	Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies. Drug Discovery Today, 2017, 22, 1045-1055.	3.2	16
641	Exaptation, serendipity and aging. Mechanisms of Ageing and Development, 2017, 163, 30-35.	2.2	6
642	Application of Biocatalysis to onâ€DNA Carbohydrate Library Synthesis. ChemBioChem, 2017, 18, 858-863.	1.3	60
643	Comparative Study of the Synthesis and Structural and Physicochemical Properties of Diketopiperazines vs Aza-diketopiperazines. Journal of Organic Chemistry, 2017, 82, 3239-3244.	1.7	7
644	Bioengineered 3D Glial Cell Culture Systems and Applications for Neurodegeneration and Neuroinflammation. SLAS Discovery, 2017, 22, 583-601.	1.4	55
645	A screening strategy for the discovery of drugs that reduce $C/EBP\hat{l}^2$ -LIP translation with potential calorie restriction mimetic properties. Scientific Reports, 2017, 7, 42603.	1.6	12
646	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature Reviews Microbiology, 2017, 15, 217-231.	13.6	315
647	Enabling 1536-Well High-Throughput Cell-Based Screening through the Application of Novel Centrifugal Plate Washing. SLAS Discovery, 2017, 22, 732-742.	1.4	10
648	Analysis of live cell images: Methods, tools and opportunities. Methods, 2017, 115, 65-79.	1.9	65
649	Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs. JACC Basic To Translational Science, 2017, 2, 1-12.	1.9	34
650	Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery. Drug Discovery Today, 2017, 22, 994-1007.	3.2	28
651	Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue. Organic and Biomolecular Chemistry, 2017, 15, 2501-2506.	1.5	20
652	Application of a New Scaffold Concept for Computational Target Deconvolution of Chemical Cancer Cell Line Screens. ACS Omega, 2017, 2, 1463-1468.	1.6	14
653	Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex. Chemical Communications, 2017, 53, 5167-5170.	2.2	9

#	Article	IF	CITATIONS
654	Evolution of Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 234-238.	1.2	34
655	Targeting neuronal function for CNS drug discovery. Drug Discovery Today: Technologies, 2017, 23, 17-25.	4.0	4
656	Natural and Synthetic Flavonoids as Potent <i>Mycobacterium tuberculosis</i> UGM Inhibitors. Chemistry - A European Journal, 2017, 23, 10423-10429.	1.7	31
657	3D bioprinting for drug discovery and development in pharmaceutics. Acta Biomaterialia, 2017, 57, 26-46.	4.1	229
658	Phenotypic chemical biology for predicting safety and efficacy. Drug Discovery Today: Technologies, 2017, 23, 53-60.	4.0	29
659	Outlook for the Future. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 421-447.	0.2	O
660	Little Fish, Big Data: Zebrafish as a Model for Cardiovascular and Metabolic Disease. Physiological Reviews, 2017, 97, 889-938.	13.1	250
661	Pharmaceutical Industry Performance. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 3-25.	0.2	O
662	Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases. Pharmacological Reports, 2017, 69, 746-756.	1.5	39
663	Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors. Methods, 2017, 128, 78-94.	1.9	37
664	Kinetic Image Cytometry for Predicting Arrhythmias Using Human Stem Cell-Derived Cardiomyocytes. Methods in Pharmacology and Toxicology, 2017, , 153-171.	0.1	1
665	A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 2017, 16, 19-34.	21.5	1,608
666	A Tryptoline Ringâ€Distortion Strategy Leads to Complex and Diverse Biologically Active Molecules from the Indole Alkaloid Yohimbine. Chemistry - A European Journal, 2017, 23, 4327-4335.	1.7	61
667	Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury. Nephron, 2017, 137, 268-272.	0.9	9
668	Cascade Synthesis of Benzimidazole-Linked Pyrroles via Copper Catalyzed Oxidative Cyclization and Ketonization. Organic Letters, 2017, 19, 3103-3106.	2.4	13
669	Documenting and harnessing the biological potential of molecules in Distributed Drug Discovery (D3) virtual catalogs. Chemical Biology and Drug Design, 2017, 90, 909-918.	1.5	6
670	Leishmaniasis drug discovery: recent progress and challenges in assay development. Drug Discovery Today, 2017, 22, 1516-1531.	3.2	145
671	Predicting the Reliability of Drug-target Interaction Predictions with Maximum Coverage of Target Space. Scientific Reports, 2017, 7, 3820.	1.6	62

#	Article	IF	CITATIONS
672	Major achievements of evidence-based traditional Chinese medicine in treating major diseases. Biochemical Pharmacology, 2017, 139, 94-104.	2.0	123
673	In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach. Drug Discovery Today: Technologies, 2017, 23, 45-52.	4.0	15
674	Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discovery, 2017, 22, 456-472.	1.4	617
675	Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter. British Journal of Pharmacology, 2017, 174, 2152-2153.	2.7	6
676	Future of Drug Discovery., 2017,, 609-629.		3
677	Synthesis of 3,5-Disubstituted Isoxazoles Containing Privileged Substructures with a Diverse Display of Polar Surface Area. ACS Combinatorial Science, 2017, 19, 407-413.	3.8	15
678	Anti-tubercular drug discovery: in silico implications and challenges. European Journal of Pharmaceutical Sciences, $2017$ , $104$ , $1-15$ .	1.9	8
679	Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. Drug Discovery Today, 2017, 22, 805-813.	3.2	20
680	High-resolution phenotypic profiling of natural products-induced effects on the single-cell level. Scientific Reports, 2017, 7, 44472.	1.6	19
681	Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease. Stem Cell Reports, 2017, 8, 870-882.	2.3	53
682	Copper and Antibiotics. Advances in Microbial Physiology, 2017, 70, 193-260.	1.0	96
683	Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discovery, 0, , 247255521769679.	1.4	10
684	RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opinion on Investigational Drugs, 2017, 26, 109-119.	1.9	45
685	Phenotypic assays for analyses of pluripotent stem cell–derived cardiomyocytes. Journal of Molecular Recognition, 2017, 30, e2602.	1.1	15
686	High content analysis in amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences, 2017, 80, 180-191.	1.0	10
687	Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery. Advances in Biochemical Engineering/Biotechnology, 2017, 163, 207-220.	0.6	7
688	APOL1 Nephropathy: A Population Genetics and Evolutionary Medicine Detective Story. Seminars in Nephrology, 2017, 37, 490-507.	0.6	37
689	Phenotypic Screening. Annual Reports in Medicinal Chemistry, 2017, 50, 263-299.	0.5	6

#	Article	IF	CITATIONS
690	Orally Active Epoxyeicosatrienoic Acid Analogs. Journal of Cardiovascular Pharmacology, 2017, 70, 211-224.	0.8	42
691	Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds. Bioorganic and Medicinal Chemistry, 2017, 25, 6332-6344.	1.4	17
692	The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 8989-9002.	2.9	44
693	Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity inÂvitro. European Journal of Medicinal Chemistry, 2017, 140, 421-434.	2.6	14
694	An effective HIV-1 integrase inhibitor screening platform: Rationality validation of drug screening, conformational mobility and molecular recognition analysis for PFV integrase complex with viral DNA. Journal of Molecular Graphics and Modelling, 2017, 78, 96-109.	1.3	3
695	Distinct <i>in vivo</i> target occupancy by bivalentâ€and inducedâ€fitâ€like binding drugs. British Journal of Pharmacology, 2017, 174, 4233-4246.	2.7	9
696	A Photoaffinity Labeling-Based Chemoproteomics Strategy for Unbiased Target Deconvolution of Small Molecule Drug Candidates. Methods in Molecular Biology, 2017, 1647, 1-18.	0.4	20
697	Target Identification Using Cell Permeable and Cleavable Chloroalkane Derivatized Small Molecules. Methods in Molecular Biology, 2017, 1647, 91-108.	0.4	3
698	Synthesis and evaluation of the NSCLC anti-cancer activity and physical properties of 4-aryl- N -phenylpyrimidin-2-amines. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4749-4754.	1.0	9
699	A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules. Journal of Visualized Experiments, 2017, , .	0.2	10
700	Bioactivity-Guided Fractionation of Pine Needle Reveals Catechin as an Anti-hypertension Agent via Inhibiting Angiotensin-Converting Enzyme. Scientific Reports, 2017, 7, 8867.	1.6	16
701	High-throughput flow cytometry for drug discovery: principles, applications, and case studies. Drug Discovery Today, 2017, 22, 1844-1850.	3.2	34
702	Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration–Approved Drugs. Pharmacological Reviews, 2017, 69, 479-496.	7.1	58
703	Contemporary Approaches for Malaria Drug Discovery. , 2017, , 45-56.		0
705	Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening. Journal of Biotechnology, 2017, 260, 18-30.	1.9	17
706	Drug discovery and development for rare genetic disorders. American Journal of Medical Genetics, Part A, 2017, 173, 2307-2322.	0.7	64
707	Action sequencing in the spontaneous swimming behavior of zebrafish larvae - implications for drug development. Scientific Reports, 2017, 7, 3191.	1.6	17
708	Deoxyarbutin displays antitumour activity against melanoma in vitro and in vivo through a p38-mediated mitochondria associated apoptotic pathway. Scientific Reports, 2017, 7, 7197.	1.6	9

#	Article	IF	CITATIONS
709	Protein-ligand binding affinity determination by the waterLOGSY method: An optimised approach considering ligand rebinding. Scientific Reports, 2017, 7, 43727.	1.6	30
710	Logic Modeling in Quantitative Systems Pharmacology. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 499-511.	1.3	25
711	Microfluidic systems for high-throughput and high-content screening using the nematode Caenorhabditis elegans. Lab on A Chip, 2017, 17, 3736-3759.	3.1	53
712	How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice. Assay and Drug Development Technologies, 2017, 15, 239-246.	0.6	58
713	High content analysis of phagocytic activity and cell morphology with PuntoMorph. Journal of Neuroscience Methods, 2017, 291, 43-50.	1.3	10
715	Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins. Neuron, 2017, 96, 989-1001.	3.8	56
718	Applications of MEMS to Cell Biology. Springer Handbooks, 2017, , 587-616.	0.3	2
719	Synthesis of 2-Alkoxy/Thioalkoxy Benzo[ <i>d</i> ) jimidazoles and 2-Thione Benzo[ <i>d</i> ) jimidazoles via a Phase-Based, Chemoselective Reaction. ACS Combinatorial Science, 2017, 19, 738-747.	3.8	2
720	Empirical drug discovery: a view from the proteome. Drug Discovery Today: Technologies, 2017, 23, 1-5.	4.0	6
721	Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities. Clinical Therapeutics, 2017, 39, 1409-1425.e20.	1.1	23
722	Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. Drug Discovery Today: Technologies, 2017, 23, 7-16.	4.0	11
723	Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. Cancer Cell, 2017, 32, 9-25.	7.7	183
724	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	4.0	74
725	Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 2017, 16, 531-543.	21.5	607
726	Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 1571-1584.	1.4	10
727	Using Big Data to Discover Diagnostics and Therapeutics forÂGastrointestinal and Liver Diseases. Gastroenterology, 2017, 152, 53-67.e3.	0.6	61
728	Phenotypic Screen for Cardiac Regeneration Identifies Molecules with Differential Activity in Human Epicardium-Derived Cells versus Cardiac Fibroblasts. ACS Chemical Biology, 2017, 12, 132-141.	1.6	17
729	Drug discovery for hearing loss: Phenotypic screening of chemical compounds on primary cultures of the spiral ganglion. Hearing Research, 2017, 349, 177-181.	0.9	12

#	Article	IF	CITATIONS
730	Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration. Molecular and Cellular Neurosciences, 2017, 80, 161-169.	1.0	20
731	AGEs/RAGE-Related Neurodegeneration: <i>daf-16</i> as a Mediator, Insulin as an Ameliorant, and <i>C. elegans</i> as an Expedient Research Model. Chemical Research in Toxicology, 2017, 30, 38-42.	1.7	3
732	CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?. Annual Review of Pharmacology and Toxicology, 2017, 57, 171-187.	4.2	32
733	Largeâ€scale imageâ€based screening and profiling of cellular phenotypes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 115-125.	1.1	55
734	Phenotypic screening meets natural products in drug discoveryâ€. Bioscience, Biotechnology and Biochemistry, 2017, 81, 28-31.	0.6	10
735	The path to producing pharmaceuticals from natural products uncovered by academia—from the perspective of a science coordinatorâ€. Bioscience, Biotechnology and Biochemistry, 2017, 81, 38-42.	0.6	2
736	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	2.9	47
737	Overcoming the Declining Trends inÂlnnovation and Investment in Cardiovascular Therapeutics. JACC Basic To Translational Science, 2017, 2, 613-625.	1.9	20
738	Oceans. , 2017, , 493-554.		7
739	Label-Free Screening Technologies. , 2017, , 416-433.		1
740	Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. Frontiers in Pharmacology, 2017, 8, 155.	1.6	18
741	Relations between Effects and Structure of Small Bicyclic Molecules on the Complex Model System Saccharomyces cerevisiae. Frontiers in Pharmacology, 2017, 8, 170.	1.6	0
742	Phenotypic Screen Identifies a Small Molecule Modulating ERK2 and Promoting Stem Cell Proliferation. Frontiers in Pharmacology, 2017, 8, 726.	1.6	3
743	Development of the Digital Arthritis Index, a Novel Metric to Measure Disease Parameters in a Rat Model of Rheumatoid Arthritis. Frontiers in Pharmacology, 2017, 8, 818.	1.6	33
744	The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery. Frontiers in Pharmacology, 2017, 8, 894.	1.6	14
746	Drug Repurposing Review., 2017,, 11-47.		5
747	Future of Medicinal Chemistry: Next-Generation Therapeutics. , 2017, , 326-348.		0
748	Toxicological and Pharmacological Use of Anticancer Compounds. , 2017, , 203-231.		1

#	Article	IF	Citations
749	Click Chemistry in Medicinal Chemistry for Comprehensive Medicinal Chemistry III., 2017, , 296-325.		0
750	Demonstration Study: A Protocol to Combine Online Tools and Databases for Identifying Potentially Repurposable Drugs. Data, 2017, 2, 15.	1.2	6
751	Utilizing Zebrafish Visual Behaviors in Drug Screening for Retinal Degeneration. International Journal of Molecular Sciences, 2017, 18, 1185.	1.8	46
752	Systematic integration of biomedical knowledge prioritizes drugs for repurposing. ELife, 2017, 6, .	2.8	333
753	Antimicrobial Metallodrugs. , 2017, , 205-243.		7
754	Bioinformatics and Drug Discovery. Current Topics in Medicinal Chemistry, 2017, 17, 1709-1726.	1.0	128
755	Contemporary Considerations for Discovering a Successful Medicine., 2017,, 560-576.		0
756	Hit and Lead Generation Strategies. , 2017, , 33-63.		2
757	Modeling timelines for translational science in cancer; the impact of technological maturation. PLoS ONE, 2017, 12, e0174538.	1.1	11
758	A Brief Review of Drug Discovery Research for Human African Trypanosomiasis. Current Medicinal Chemistry, 2017, 24, 701-717.	1.2	21
759	Drug Discovery Technologies: Current and Future Trends. , 2017, , 1-32.		4
760	Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface $\hat{a}^{-}\uparrow$ . , 2017, , .		4
761	Cell and small animal models for phenotypic drug discovery. Drug Design, Development and Therapy, 2017, Volume 11, 1957-1967.	2.0	34
762	Recent Progress in Free Energy Methods. , 2017, , 34-50.		3
763	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery., 2017,, 64-93.		0
764	Screening and identification of novel biologically active natural compounds. F1000Research, 2017, 6, 783.	0.8	32
765	Predicting Target and Chemical Druggability., 2017,, 429-439.		2
766	Discovery and optimization of 2-thio-5-amino substituted benzoquinones as potent anticancer agents. European Journal of Medicinal Chemistry, 2018, 149, 1-9.	2.6	5

#	Article	IF	CITATIONS
767	High-throughput organ-on-a-chip systems: Current status and remaining challenges. Current Opinion in Biomedical Engineering, 2018, 6, 33-41.	1.8	113
768	Identification of glia phenotype modulators based on select glial function regulatory signaling pathways. Expert Opinion on Drug Discovery, 2018, 13, 627-641.	2.5	8
770	Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease. Journal of Huntington's Disease, 2018, 7, 1-16.	0.9	19
771	Structure-based design of targeted covalent inhibitors. Chemical Society Reviews, 2018, 47, 3816-3830.	18.7	229
772	A focused library synthesis and cytotoxicity of quinones derived from the natural product bolinaquinone. Royal Society Open Science, 2018, 5, 171189.	1.1	7
773	Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chemical Biology, 2018, 13, 1380-1387.	1.6	13
774	DDR: efficient computational method to predict drug–target interactions using graph mining and machine learning approaches. Bioinformatics, 2018, 34, 1164-1173.	1.8	158
775	Contribution of NIH funding to new drug approvals 2010–2016. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2329-2334.	3.3	150
776	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery, 2018, 17, 167-181.	21.5	294
777	The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?. Advanced Healthcare Materials, 2018, 7, 1701174.	3.9	66
778	Manipulating cell fate while confronting reproducibility concerns. Biochemical Pharmacology, 2018, 151, 144-156.	2.0	6
779	Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies. Journal of Pharmaceutical Analysis, 2018, 8, 138-146.	2.4	10
780	Translating Knowledge Into Therapy for Acute Kidney Injury. Seminars in Nephrology, 2018, 38, 88-97.	0.6	22
781	Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene, 2018, 37, 403-414.	2.6	74
782	Where do we go from here? Membrane protein research beyond the structure-function horizon. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 801-803.	1.4	1
783	Post-Ugi Cascade Transformations for Accessing Diverse Chromenopyrrole Collections. Organic Letters, 2018, 20, 836-839.	2.4	34
784	Construction of 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Library with a High Level of Skeletal Diversity Based on Branching Diversity-Oriented Synthesis on Solid-Phase Supports. ACS Combinatorial Science, 2018, 20, 82-97.	3.8	8
785	Predicting inhibitory and activatory drug targets by chemically and genetically perturbed transcriptome signatures. Scientific Reports, 2018, 8, 156.	1.6	43

#	Article	IF	CITATIONS
786	High-Content Screening of the Medicines for Malaria Venture Pathogen Box for Plasmodium falciparum Digestive Vacuole-Disrupting Molecules Reveals Valuable Starting Points for Drug Discovery. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	21
787	Drug Discovery and Development. , 2018, , 19-32.		37
788	Biased signalling: from simple switches to allosteric microprocessors. Nature Reviews Drug Discovery, 2018, 17, 243-260.	21.5	524
789	Image-Based Profiling Can Discriminate the Effects of Inhibitors on Signaling Pathways under Differential Ligand Stimulation. SLAS Discovery, 2018, 23, 330-340.	1.4	2
790	Discovery and cellular stress pathway analysis of 1,4-naphthoquinone derivatives with novel, highly potent broad-spectrum anticancer activity. Journal of Biomedical Science, 2018, 25, 12.	2.6	12
791	Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective. Journal of Medicinal Chemistry, 2018, 61, 8504-8535.	2.9	55
792	Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs. MedChemComm, 2018, 9, 1017-1032.	3.5	5
793	Machine Learning Enables Live Label-Free Phenotypic Screening in Three Dimensions. Assay and Drug Development Technologies, 2018, 16, 51-63.	0.6	8
794	Identification of Novel Molecules Targeting Cancer Stem Cells. Methods in Molecular Biology, 2018, 1765, 333-347.	0.4	4
795	Comparative Proteomics of Dying and Surviving Cancer Cells Improves the Identification of Drug Targets and Sheds Light on Cell Life/Death Decisions. Molecular and Cellular Proteomics, 2018, 17, 1144-1155.	2.5	25
796	Stimulation of alpha2-adrenergic receptors impairs influenza virus infection. Scientific Reports, 2018, 8, 4631.	1.6	11
797	Plate-Based Phenotypic Screening for Pain Using Human iPSC-Derived Sensory Neurons. SLAS Discovery, 2018, 23, 585-596.	1.4	30
798	Whole-organism phenotypic screening for anti-infectives promoting host health. Nature Chemical Biology, 2018, 14, 331-341.	3.9	14
799	Discovery of Bioactive Natural Products for the Treatment of Acute Respiratory Infections – An Integrated Approach. Planta Medica, 2018, 84, 684-695.	0.7	18
800	Algorithmic Mapping and Characterization of the Drug-Induced Phenotypic-Response Space of Parasites Causing Schistosomiasis. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2018, 15, 469-481.	1.9	13
801	Drug repurposing from the perspective of pharmaceutical companies. British Journal of Pharmacology, 2018, 175, 168-180.	2.7	281
802	The application of molecular topology for ulcerative colitis drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 89-101.	2.5	2
803	Controlling Differentiation of Stem Cells for Developing Personalized Organâ€onâ€Chip Platforms. Advanced Healthcare Materials, 2018, 7, 1700426.	3.9	65

#	ARTICLE	IF	CITATIONS
804	CHEMGENIE: integration of chemogenomics data for applications in chemical biology. Drug Discovery Today, 2018, 23, 151-160.	3.2	13
805	A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers. British Journal of Clinical Pharmacology, 2018, 84, 482-489.	1.1	9
806	Cheminformatics in the Service of GPCR Drug Discovery. Methods in Molecular Biology, 2018, 1705, 395-411.	0.4	4
807	Compound Functional Prediction Using Multiple Unrelated Morphological Profiling Assays. SLAS Technology, 2018, 23, 243-251.	1.0	16
808	Utilization of Multidimensional Data in the Analysis of Ultra-High-Throughput High Content Phenotypic Screens. Methods in Molecular Biology, 2018, 1683, 267-290.	0.4	4
809	Determining Dose-Response Characteristics of Molecular Perturbations in Whole-Organism Assays Using Biological Imaging and Machine Learning. , 2018, , .		4
810	Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells. Oncotarget, 2018, 9, 9838-9851.	0.8	17
811	Cell-Based Screening to Identify Cytoprotective Compounds. , 0, , .		0
812	OBSOLETE: Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Advancing Cardiovascular Medicine. , $2018,  ,  .$		0
813	Step I: Target Identification. , 2018, , 1-31.		0
814	High Content, Phenotypic Assays and Screens for Compounds Modulating Cellular Processes in Primary Neurons. Methods in Enzymology, 2018, 610, 219-250.	0.4	7
815	Is the Pace of Biomedical Innovation Slowing?. Perspectives in Biology and Medicine, 2018, 61, 584-593.	0.3	5
816	Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish. Frontiers in Cell and Developmental Biology, 2018, 6, 163.	1.8	30
817	Predicting protein targets for drug-like compounds using transcriptomics. PLoS Computational Biology, 2018, 14, e1006651.	1.5	51
818	Strategies towards expansion of chemical space of natural product-based compounds to enable drug discovery. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	2
819	Advances in the Use of Zebrafish in Developmental Toxicology: Linking Genetics, Behavior, and High-Throughput Testing Strategies., 2018,, 298-326.		1
820	High Content Screening of Small Molecule Modulators Targeting Heat Shock Response Pathway. Heat Shock Proteins, 2018, , 141-165.	0.2	1
821	Pt-induced crosslinks promote target enrichment and protection from serum nucleases. Journal of Inorganic Biochemistry, 2018, 189, 124-133.	1.5	6

#	Article	IF	CITATIONS
822	Dynamic Proteomics Reveals High Plasticity of Cellular Proteome: Growthâ€Related and Drugâ€Induced Changes in Cancer Cells are Comparable. Proteomics, 2018, 18, e1800118.	1.3	14
823	High-Throughput Screening. , 2018, , 278-278.		0
824	Target Identification Using Chemical Probes. Methods in Enzymology, 2018, 610, 27-58.	0.4	9
825	Reactive Oxygen Species Responsive Naturally Occurring Phenolic-Based Polymeric Prodrug. Advances in Experimental Medicine and Biology, 2018, 1078, 291-301.	0.8	6
826	High-throughput screening for selective appetite modulators: A multibehavioral and translational drug discovery strategy. Science Advances, 2018, 4, eaav1966.	4.7	46
827	High-throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell derived neurons. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	63
828	Current Screening Methodologies in Drug Discovery for Selected Human Diseases. Marine Drugs, 2018, 16, 279.	2.2	73
829	A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia. Npj Precision Oncology, 2018, 2, 18.	2.3	14
830	The mouse as a model for neuropsychiatric drug development. Current Biology, 2018, 28, R909-R914.	1.8	26
831	Review of Drug Repositioning Approaches and Resources. International Journal of Biological Sciences, 2018, 14, 1232-1244.	2.6	429
832	Machine learning and image-based profiling in drug discovery. Current Opinion in Systems Biology, 2018, 10, 43-52.	1.3	128
833	A Scalable Pipeline for High-Throughput Flow Cytometry. SLAS Discovery, 2018, 23, 708-718.	1.4	6
834	The Science and Technology Challenge: How to Find New Drugs. , 2018, , 41-61.		0
835	Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. , 2018, 192, 1-19.		67
836	Leishmaniasis treatment update of possibilities for drug repurposing. Frontiers in Bioscience - Landmark, 2018, 23, 967-996.	3.0	53
837	lonophoric effects of the antitubercular drug bedaquiline. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7326-7331.	3.3	85
838	A Minimalist Approach to the Design of Complexityâ€Enriched Bioactive Small Molecules: Discovery of Phenanthrenoid Mimics as Antiproliferative Agents. ChemMedChem, 2018, 13, 1732-1740.	1.6	2
839	Receptor Binding Assays and Drug Discovery. Advances in Pharmacology, 2018, 82, 21-34.	1,2	4

#	Article	IF	CITATIONS
840	Immuno-detection by sequencing enables large-scale high-dimensional phenotyping in cells. Nature Communications, 2018, 9, 2384.	5.8	17
841	Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?. Current Opinion in Pharmacology, 2018, 42, 55-61.	1.7	19
842	From Medicinal Chemistry to Human Health: Current Approaches to Drug Discovery for Cancer and Neglected Tropical Diseases. Anais Da Academia Brasileira De Ciencias, 2018, 90, 645-661.	0.3	15
843	Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery. Frontiers in Chemistry, 2018, 6, 315.	1.8	105
844	Filling the drug discovery gap: is high-content screening the missing link?. Current Opinion in Pharmacology, 2018, 42, 40-45.	1.7	21
845	Discovery of 2,4-dimethoxypyridines as novel autophagy inhibitors. Tetrahedron, 2018, 74, 4531-4537.	1.0	8
846	Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. Frontiers in Pharmacology, 2018, 9, 703.	1.6	78
847	Preformulation in Drug Research and Pharmaceutical Product Development. , 2018, , 1-55.		4
848	Zebrafish assay development for cardiovascular disease mechanism and drug discovery. Progress in Biophysics and Molecular Biology, 2018, 138, 126-131.	1.4	9
849	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	1.0	140
850	Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. Journal of Medicinal Chemistry, 2018, 61, 10345-10374.	2.9	67
851	Chemoproteomics and Chemical Probes for Target Discovery. Trends in Biotechnology, 2018, 36, 1275-1286.	4.9	86
852	High-Dimensional Profiling: The Theta Comparative Cell Scoring Method. Methods in Molecular Biology, 2018, 1787, 171-181.	0.4	3
854	Modulation of Threat Response in Larval Zebrafish. Methods in Molecular Biology, 2018, 1787, 147-159.	0.4	0
855	Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments. Methods in Molecular Biology, 2018, 1787, 115-127.	0.4	5
856	Link between a high <i>k</i> <sub>on</sub> for drug binding and a fast clinical action: to be or not to be?. MedChemComm, 2018, 9, 1426-1438.	3.5	15
857	Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery. Journal of Visualized Experiments, 2018, , .	0.2	8
858	Facile One-Pot Parallel Synthesis of 3-Amino-1,2,4-triazoles. ACS Combinatorial Science, 2018, 20, 461-466.	3.8	13

#	Article	IF	CITATIONS
859	Integration of Lead Discovery Tactics and the Evolution of the Lead Discovery Toolbox. SLAS Discovery, 2018, 23, 881-897.	1.4	25
860	Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells. PLoS ONE, 2018, 13, e0189247.	1.1	7
861	<i>Assay Guidance Manual</i> : Quantitative Biology and Pharmacology in Preclinical Drug Discovery. Clinical and Translational Science, 2018, 11, 461-470.	1.5	38
862	Introduction to biological complexity as a missing link in drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 753-763.	2.5	10
863	Requirements of skin tissue models for high-throughput screening. , 2018, , 421-440.		3
864	Intravenous xenogeneic human cardiosphere-derived cell extracellular vesicles (exosomes) improves behavioral function in small-clot embolized rabbits. Experimental Neurology, 2018, 307, 109-117.	2.0	29
865	A11, a novel diaryl acylhydrazone derivative, exerts neuroprotection against ischemic injury in vitro and in vivo. Acta Pharmacologica Sinica, 2019, 40, 160-169.	2.8	11
866	Chemoinformatics: From Chemical Art to Chemistry in Silico. , 2019, , 601-618.		5
867	SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D <sub>2</sub> Receptor Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 1-14.	1.3	118
868	Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work. European Journal of Medicinal Chemistry, 2019, 182, 111602.	2.6	47
869	Enhanced Antibiotic Discovery by PROSPECTing. Biochemistry, 2019, 58, 3475-3476.	1.2	0
870	Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome. Brain Communications, 2019, 1, fcz008.	1.5	34
871	PromISR-6, a Guanabenz Analogue, Improves Cellular Survival in an Experimental Model of Huntington's Disease. ACS Chemical Neuroscience, 2019, 10, 3575-3589.	1.7	8
872	(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice. Neurobiology of Disease, 2019, 130, 104528.	2.1	33
873	Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice. European Journal of Pharmacology, 2019, 859, 172523.	1.7	20
874	Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes. Frontiers in Pharmacology, 2019, 10, 847.	1.6	31
875	Evaluation and Identification of the Neuroprotective Compounds of Xiaoxuming Decoction by Machine Learning: A Novel Mode to Explore the Combination Rules in Traditional Chinese Medicine Prescription. BioMed Research International, 2019, 2019, 1-14.	0.9	7
876	Efficacy of Compounds Isolated from Streptomyces olivaceus against the Morphogenesis and Virulence of Candida albicans. Marine Drugs, 2019, 17, 442.	2.2	10

#	Article	IF	CITATIONS
877	The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery. Cell Chemical Biology, 2019, 26, 1050-1066.	2.5	31
878	Spirocyclic Tetramates by Sequential Knoevenagel and [1,5]-Prototropic Shift. Journal of Organic Chemistry, 2019, 84, 9671-9683.	1.7	8
879	Emerging therapeutic potentials of dualâ€acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. Archiv Der Pharmazie, 2019, 352, e1900177.	2.1	99
880	STarFish: A Stacked Ensemble Target Fishing Approach and its Application to Natural Products. Journal of Chemical Information and Modeling, 2019, 59, 4906-4920.	2.5	27
881	Employing a ZTP Riboswitch to Detect Bacterial Folate Biosynthesis Inhibitors in a Small Molecule High-Throughput Screen. ACS Chemical Biology, 2019, 14, 2841-2850.	1.6	13
882	MitoToxy assay: A novel cell-based method for the assessment of metabolic toxicity in a multiwell plate format using a lactate FRET nanosensor, Laconic. PLoS ONE, 2019, 14, e0224527.	1.1	12
883	Elucidating Compound Mechanism of Action and Predicting Cytotoxicity Using Machine Learning Approaches, Taking Prediction Confidence into Account. Current Protocols in Chemical Biology, 2019, 11, e73.	1.7	1
884	Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs. Nature Chemistry, 2019, 11, 1113-1123.	6.6	93
886	11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells. Scientific Reports, 2019, 9, 11916.	1.6	2
887	JTE-607, a multiple cytokine production inhibitor, targets CPSF3 and inhibits pre-mRNA processing. Biochemical and Biophysical Research Communications, 2019, 518, 32-37.	1.0	27
888	Identification of 2,6-Disubstituted $3 < i > H < / i > -Imidazo [4,5 - < i > b < / i > ]$ pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells. Journal of Medicinal Chemistry, 2019, 62, 9175-9187.	2.9	6
889	Human Protein Complex Signatures for Drug Repositioning. , 2019, , .		3
890	Hydration of Aromatic Heterocycles as an Adversary of π-Stacking. Journal of Chemical Information and Modeling, 2019, 59, 4209-4219.	2.5	11
891	Bengamides display potent activity against drug-resistant Mycobacterium tuberculosis. Scientific Reports, 2019, 9, 14396.	1.6	10
892	Turbo Analytics: Applications of Big Data and HPC in Drug Discovery. Challenges and Advances in Computational Chemistry and Physics, 2019, , 347-374.	0.6	1
893	A divergent synthetic pathway for pyrimidine-embedded medium-sized azacycles through an N-quaternizing strategy. Chemical Science, 2019, 10, 569-575.	3.7	17
894	Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model. Scientific Reports, 2019, 9, 530.	1.6	7
895	Identifying a novel anticancer agent with microtubule-stabilizing effects through computational cell-based bioactivity prediction models and bioassays. Organic and Biomolecular Chemistry, 2019, 17, 1519-1530.	1.5	14

#	Article	IF	CITATIONS
896	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model. Bioorganic and Medicinal Chemistry, 2019, 27, 865-879.	1.4	11
897	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. ACS Medicinal Chemistry Letters, 2019, 10, 558-563.	1.3	16
898	Macrophage Cytological Profiling and Anti-Inflammatory Drug Discovery. Assay and Drug Development Technologies, 2019, 17, 14-16.	0.6	3
899	Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry, 2019, 1, 612-624.	4.4	46
900	Heart Rate Variability as a Translational Biomarker for Emotional and Cognitive Deficits. Handbook of Behavioral Neuroscience, 2019, , 199-212.	0.7	4
901	Strategies for the Diversity-Oriented Synthesis of Macrocycles. Chemical Reviews, 2019, 119, 10288-10317.	23.0	129
902	Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133+ HCC. Chemico-Biological Interactions, 2019, 309, 108713.	1.7	12
903	Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases. Trends in Parasitology, 2019, 35, 559-570.	1.5	64
904	Exploring Bioactive Marine Natural Products and Identification of Their Molecular Targets. , 2019, , 291-303.		0
905	A Structure-Based Drug Discovery Paradigm. International Journal of Molecular Sciences, 2019, 20, 2783.	1.8	350
906	Quantitative analysis of operators' flow line in the cell culture for controlled manual operation. Regenerative Therapy, 2019, 12, 43-54.	1.4	3
907	Combined Scaffold Evaluation and Systemsâ€Level Transcriptomeâ€Based Analysis for Accelerated Lead Optimization Reveals Ribosomal Targeting Spirooxindole Cyclopropanes. ChemMedChem, 2019, 14, 1653-1661.	1.6	11
908	Using artificial intelligence methods to speed up drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 769-777.	2.5	54
909	Drug repositioning of herbal compounds via a machine-learning approach. BMC Bioinformatics, 2019, 20, 247.	1.2	37
910	Microbial Fraction Library: A Screening Source for Drug Discovery. , 2019, , 1-20.		0
911	Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae. Frontiers in Pharmacology, 2019, 10, 508.	1.6	9
912	High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs. Stem Cell Reports, 2019, 12, 1389-1403.	2.3	43
913	Structure-activity relationships of novel dithiocarbamates containing $\hat{l}\pm,\hat{l}^2$ -unsaturated ketone fragment as potent anticancer agents. Medicinal Chemistry Research, 2019, 28, 1027-1038.	1.1	1

#	Article	IF	CITATIONS
914	Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research. Npj Regenerative Medicine, 2019, 4, 10.	2.5	34
915	Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis. Nature Chemistry, 2019, 11, 521-532.	6.6	159
916	Drug discovery strategies for acute radiation syndrome. Expert Opinion on Drug Discovery, 2019, 14, 701-715.	2.5	25
917	Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 434-454.	3.3	131
918	New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design. Biochemistry, 2019, 58, 5234-5244.	1.2	64
919	Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin. Journal of Medicinal Chemistry, 2019, 62, 4949-4966.	2.9	27
920	The compromise of virtual screening and its impact on drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 619-637.	2.5	59
921	Activity-Based DNA-Encoded Library Screening. ACS Combinatorial Science, 2019, 21, 425-435.	3.8	56
922	In Silico Drug Design Methods for Drug Repurposing. , 2019, , 47-84.		10
923	Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. Frontiers in Immunology, 2019, 10, 531.	2.2	95
924	Emerging drug development technologies targeting ubiquitination for cancer therapeutics., 2019, 199, 139-154.		52
925	3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis. SLAS Discovery, 2019, 24, 615-627.	1.4	116
926	Computational Drug Repurposing for Neurodegenerative Diseases. , 2019, , 85-118.		6
927	In Silico Repurposing of Cell Cycle Modulators for Cancer Treatment. , 2019, , 255-279.		0
928	Cancer Treatment by Using Traditional Chinese Medicine: Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy. Current Medicinal Chemistry, 2019, 25, 5128-5141.	1.2	43
929	Encircling the regions of the pharmacogenomic landscape that determine drug response. Genome Medicine, 2019, 11, 17.	3.6	14
930	What role do pharmaceuticals play in the treatment of Peyronie's disease and is there a need for new emerging drugs?. Expert Opinion on Emerging Drugs, 2019, 24, 1-4.	1.0	8
931	On-chip anticancer drug screening – Recent progress in microfluidic platforms to address challenges in chemotherapy. Biosensors and Bioelectronics, 2019, 137, 236-254.	5.3	68

#	Article	IF	Citations
932	Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries. Cell Chemical Biology, 2019, 26, 765-777.e3.	2.5	59
933	Antimicrobial mechanism of reaction products of Morus notabilis (mulberry) polyphenol oxidases and chlorogenic acid. Phytochemistry, 2019, 163, 1-10.	1.4	22
934	The Impact of Chemical Biology on Drug Discovery. Israel Journal of Chemistry, 2019, 59, 29-36.	1.0	1
935	Integration of target discovery, drug discovery and drug delivery: A review on computational strategies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1554.	3.3	27
936	Label-free target identification in drug discovery via phenotypic screening. Current Opinion in Chemical Biology, 2019, 50, 66-72.	2.8	30
937	Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. Sexual Medicine Reviews, 2019, 7, 679-689.	1.5	33
938	Can We Prevent Dementia and Not Prevent Neurons from Dying?. Journal of Alzheimer's Disease, 2019, 68, 489-492.	1.2	3
939	Design and synthesis of imidazolidinone derivatives as potent antiâ€leishmanial agents by bioisosterism. Archiv Der Pharmazie, 2019, 352, 1800290.	2.1	10
940	A Phenotypic Screening Approach Using Human Treg Cells Identified Regulators of Forkhead Box p3 Expression. ACS Chemical Biology, 2019, 14, 543-553.	1.6	11
941	Network pharmacology for antiepileptogenesis: Tolerability and neuroprotective effects of novel multitargeted combination treatments in nonepileptic vs. post-status epilepticus mice. Epilepsy Research, 2019, 151, 48-66.	0.8	16
942	Label-free target identification reveals oxidative DNA damage as the mechanism of a selective cytotoxic agent. Chemical Science, 2019, 10, 3449-3458.	3.7	18
943	The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex. Topics in Medicinal Chemistry, 2019, , 27-55.	0.4	5
944	Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia. Scientific Reports, 2019, 9, 17782.	1.6	48
945	Recent advances in microfluidics for drug screening. Biomicrofluidics, 2019, 13, 061503.	1.2	53
946	The Productivity of Drug Development: A Systematic Review. , 2019, , .		1
947	The Binding of Drug Molecules to Serum Albumin: The Effect of Drug Hydrophobicity on Binding Strength and Protein Desolvation. Langmuir, 2019, 35, 17054-17060.	1.6	23
952	Drosophila as aÂModel System for theÂldentification of Pharmacological Therapies in Neurodegenerative Diseases. , 2019, , 433-467.		3
953	Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 22-27.	1.1	62

#	Article	IF	CITATIONS
954	A high-throughput chemical–genetics screen in murine adipocytes identifies insulin-regulatory pathways. Journal of Biological Chemistry, 2019, 294, 4103-4118.	1.6	9
955	High Throughput and Computational Repurposing for Neglected Diseases. Pharmaceutical Research, 2019, 36, 27.	1.7	37
956	Formatting biological big data for modern machine learning in drug discovery. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2019, 9, e1408.	6.2	17
957	CNB-001, a pleiotropic drug is efficacious in embolized agyrencephalic New Zealand white rabbits and ischemic gyrencephalic cynomolgus monkeys. Experimental Neurology, 2019, 313, 98-108.	2.0	6
958	Scalable Measurements of Intrinsic Excitability in Human iPS Cell-Derived Excitatory Neurons Using All-Optical Electrophysiology. Neurochemical Research, 2019, 44, 714-725.	1.6	15
959	α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3. International Journal of Obesity, 2019, 43, 202-216.	1.6	16
960	Direct Access to Dihydrobenzoimidazo[2,1â€ <i>a</i> ]isoquinolines through Rutheniumâ€catalyzed Formal [4+2] Annulation. Advanced Synthesis and Catalysis, 2019, 361, 535-541.	2.1	22
961	Identification of radiationâ€induced EndMT inhibitors through cellâ€based phenomic screening. FEBS Open Bio, 2019, 9, 82-91.	1.0	4
962	NMR screening and studies of target – ligand interactions. Russian Chemical Reviews, 2019, 88, 59-98.	2.5	7
963	The power of combining phenotypic and target-focused drug discovery. Drug Discovery Today, 2019, 24, 526-532.	3.2	34
964	SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping. Nucleic Acids Research, 2019, 47, D1110-D1117.	6.5	301
965	Addressing Antimicrobial Resistance through New Medicinal and Synthetic Chemistry Strategies. SLAS Discovery, 2019, 24, 419-439.	1.4	10
966	Phenotypic Screening Using Mouse and Human Stem Cell-Based Models of Neuroinflammation and Gene Expression Analysis to Study Drug Responses. Methods in Molecular Biology, 2019, 1888, 21-43.	0.4	3
967	Closed-loop discovery platform integration is needed for artificial intelligence to make an impact in drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 1-4.	2.5	37
968	Advances in Lead Generation. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 517-524.	1.0	25
969	Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening. Sensors and Actuators B: Chemical, 2019, 279, 79-86.	4.0	18
970	Identification of lamins as the molecular targets of LBL1 using a clickable photoaffinity probe. Methods in Enzymology, 2020, 633, 185-201.	0.4	2
971	Development of a Bioluminescent High-Throughput Screening Assay for Nicotinamide Mononucleotide Adenylyltransferase (NMNAT). SLAS Discovery, 2020, 25, 33-42.	1.4	9

#	Article	IF	CITATIONS
972	Repurposing antimycotic ciclopirox olamine as a promising anti-ischemic stroke agent. Acta Pharmaceutica Sinica B, 2020, 10, 434-446.	5 <b>.</b> 7	23
973	An <i>in silico</i> Approach for Integrating Phenotypic and Targetâ€based Approaches in Drug Discovery. Molecular Informatics, 2020, 39, e1900096.	1.4	8
974	A platform for target prediction of phenotypic screening hit molecules. Journal of Molecular Graphics and Modelling, 2020, 95, 107485.	1.3	1
975	Pharmaceuticals in the Urban Water Cycle. Springer Water, 2020, , 133-162.	0.2	1
976	The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons. Assay and Drug Development Technologies, 2020, 18, 97-103.	0.6	2
977	Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research. Journal of Medicinal Chemistry, 2020, 63, 1823-1840.	2.9	33
978	Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. Chemical Research in Toxicology, 2020, 33, 154-161.	1.7	9
979	Proof-of-concept that network pharmacology is effective to modify development of acquired temporal lobe epilepsy. Neurobiology of Disease, 2020, 134, 104664.	2.1	24
980	Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 5-20.	1.3	29
981	Latest trends in structure based drug design with protein targets. Advances in Protein Chemistry and Structural Biology, 2020, 121, 1-23.	1.0	5
982	Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress. Redox Biology, 2020, 28, 101374.	3.9	9
983	Diversity & Divers	1.4	6
984	Fostering practice-oriented and use-inspired science in biomedical research. Research Policy, 2020, 49, 103900.	3.3	8
985	Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid. Angewandte Chemie, 2020, 132, 2441-2449.	1.6	1
986	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	1.8	17
987	CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma. Nature Chemical Biology, 2020, 16, 50-59.	3.9	59
988	Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid. Angewandte Chemie - International Edition, 2020, 59, 2420-2428.	7.2	31
989	Phenotypic-screening generates active novel fetal globin-inducers that downregulate Bcl11a in a monkey model. Biochemical Pharmacology, 2020, 171, 113717.	2.0	3

#	Article	IF	CITATIONS
990	Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies. Cell Chemical Biology, 2020, 27, 1332-1346.	2.5	33
991	Pharmacognosy and Its Role in the System of Profile Disciplines in Pharmacy. Natural Product Communications, 2020, 15, 1934578X2094545.	0.2	2
992	Computational behavior analysis takes on drug development. Nature Neuroscience, 2020, 23, 1314-1316.	7.1	1
993	Intrinsic fluorescence properties of antimalarial pyrido[1,2-a]benzimidazoles facilitate subcellular accumulation and mechanistic studies in the human malaria parasite Plasmodium falciparum. Organic and Biomolecular Chemistry, 2020, 18, 8668-8676.	1.5	10
994	Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge. ACS Infectious Diseases, 2020, 6, 2830-2843.	1.8	17
995	Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson's Disease for Drug Identification. International Journal of Molecular Sciences, 2020, 21, 7113.	1.8	15
996	The strategies and techniques of drug discovery from natural products., 2020, 216, 107686.		95
997	Deep Learning-Based HCS Image Analysis for the Enterprise. SLAS Discovery, 2020, 25, 812-821.	1.4	12
998	Traditional Chinese Medicine and Clinical Pharmacology. , 2020, , 455-482.		16
999	Handling the Hurdles on the Way to Anti-tuberculosis Drug Development. Frontiers in Chemistry, 2020, 8, 586294.	1.8	21
1000	Multi-Institution Research and Education Collaboration Identifies New Antimicrobial Compounds. ACS Chemical Biology, 2020, 15, 3187-3196.	1.6	3
1001	Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease. British Journal of Clinical Pharmacology, 2021, 87, 2830-2837.	1.1	12
1002	Mechanism of Action and Target Identification: A Matter of Timing in Drug Discovery. IScience, 2020, 23, 101487.	1.9	41
1003	Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 14, 8-16.	1.4	54
1004	Glycohybrid molecules in medicinal chemistry: Present status and future prospective., 2020,, 451-479.		7
1005	Novel Tetrafunctional Probes Identify Target Receptors and Binding Sites of Small-Molecule Drugs from Living Systems. ACS Chemical Biology, 2020, 15, 2364-2373.	1.6	12
1006	Chemical Biology Toolsets for Drug Discovery and Target Identification., 0, , .		1
1007	Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs. Pharmaceuticals, 2020, 13, 164.	1.7	18

#	Article	IF	CITATIONS
1008	From methylene bridged diindole to carbonyl linked benzimidazoleindole: Development of potent and metabolically stable PCSK9 modulators. European Journal of Medicinal Chemistry, 2020, 206, 112678.	2.6	6
1009	Systematic Chemogenetic Library Assembly. Cell Chemical Biology, 2020, 27, 1124-1129.	2.5	37
1010	High-Throughput Screening: today's biochemical and cell-based approaches. Drug Discovery Today, 2020, 25, 1807-1821.	3.2	119
1011	In vitro Cas9-assisted editing of modular polyketide synthase genes to produce desired natural product derivatives. Nature Communications, 2020, 11, 4022.	5.8	25
1012	The Opinion of Machines. , 2020, , 16-46.		2
1013	Single-cell infrared phenomics: phenotypic screening with infrared microspectroscopy. Chemical Communications, 2020, 56, 13237-13240.	2.2	8
1014	Anti- <i>Giardia</i> Drug Discovery: Current Status and Gut Feelings. Journal of Medicinal Chemistry, 2020, 63, 13330-13354.	2.9	34
1015	Z' Does Not Need to Be > 0.5. SLAS Discovery, 2020, 25, 1000-1008.	1.4	14
1016	Revealing the structure of pharmacobehavioral space through motion sequencing. Nature Neuroscience, 2020, 23, 1433-1443.	7.1	142
1017	Human Organoids for the Study of Retinal Development and Disease. Annual Review of Vision Science, 2020, 6, 91-114.	2.3	38
1018	Microparticle-Assisted Precipitation Screening Method for Robust Drug Target Identification. Analytical Chemistry, 2020, 92, 13912-13921.	3.2	11
1019	Phase O/microdosing approaches: time for mainstream application in drug development?. Nature Reviews Drug Discovery, 2020, 19, 801-818.	21.5	55
1020	Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase. Journal of Medicinal Chemistry, 2020, 63, 9773-9786.	2.9	9
1021	BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 9595.	1.8	25
1022	The Role of Norrish Type-I Chemistry in Photoactive Drugs: An ab initio Study of a Cyclopropenone-Enediyne Drug Precursor. Frontiers in Chemistry, 2020, 8, 596590.	1.8	3
1023	Hypoglycemic activity of puerarin through modulation of oxidative stress and mitochondrial function via AMPK. Chinese Journal of Natural Medicines, 2020, 18, 818-826.	0.7	17
1024	Drug Repurposing in Neurological Diseases: Opportunities and Challenges. , 0, , .		2
1025	Dienone Compounds: Targets and Pharmacological Responses. Journal of Medicinal Chemistry, 2020, 63, 15075-15093.	2.9	13

#	Article	IF	CITATIONS
1026	Secretome-Based Screening in Target Discovery. SLAS Discovery, 2020, 25, 535-551.	1.4	15
1027	A Whole Genome-Wide Arrayed CRISPR Screen in Primary Organ Fibroblasts to Identify Regulators of Kidney Fibrosis. SLAS Discovery, 2020, 25, 591-604.	1.4	6
1028	Unwinding Fibrosis in Peyronie's Disease. Journal of Sexual Medicine, 2020, 17, 838-840.	0.3	5
1029	Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma. Cancers, 2020, 12, 1193.	1.7	8
1030	Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets. Bioorganic and Medicinal Chemistry, 2020, 28, 115546.	1.4	13
1031	Antileishmanial activity evaluation of thiazolidine-2,4-dione against Leishmania infantum and Leishmania braziliensis. Parasitology Research, 2020, 119, 2263-2274.	0.6	12
1032	<i>Cordyceps militaris</i> Exerts Anticancer Effect on Non–Small Cell Lung Cancer by Inhibiting Hedgehog Signaling via Suppression of TCTN3. Integrative Cancer Therapies, 2020, 19, 153473542092375.	0.8	13
1033	Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity. Cancers, 2020, 12, 1504.	1.7	18
1034	State-of-the-Art Technology of Model Organisms for Current Human Medicine. Diagnostics, 2020, 10, 392.	1.3	10
1035	Image-based high-content screening in drug discovery. Drug Discovery Today, 2020, 25, 1348-1361.	3.2	52
1036	High throughput generation of a resource of the human secretome in mammalian cells. New Biotechnology, 2020, 58, 45-54.	2.4	16
1037	Animal Models in Psychiatric Disorder Studies. , 2020, , .		0
1038	Phenotype screenings of drugs for combination therapy against multidrug resistance., 2020,, 207-220.		1
1039	Genetic validation of Leishmania genes essential for amastigote survival in vivo using N-myristoyltransferase as a model. Parasites and Vectors, 2020, 13, 132.	1.0	10
1040	Machine Learning in Mass Spectrometry: A MALDI-TOF MS Approach to Phenotypic Antibacterial Screening. Journal of Medicinal Chemistry, 2020, 63, 8849-8856.	2.9	18
1041	A Phenotarget Approach for Identifying an Alkaloid Interacting with the Tuberculosis Protein Rv1466. Marine Drugs, 2020, 18, 149.	2.2	11
1042	Synthetic approaches toward small molecule libraries. , 2020, , 1-34.		3
1043	Thermal Bioprinting Causes Ample Alterations of Expression of LUCAT1, IL6, CCL26, and NRN1L Genes and Massive Phosphorylation of Critical Oncogenic Drug Resistance Pathways in Breast Cancer Cells. Frontiers in Bioengineering and Biotechnology, 2020, 8, 82.	2.0	24

#	Article	IF	Citations
1044	The Resurrection of Phenotypic Drug Discovery. ACS Medicinal Chemistry Letters, 2020, 11, 1820-1828.	1.3	26
1045	How polypharmacologic is each chemogenomics library?. Future Drug Discovery, 2020, 2, FDD26.	0.8	2
1046	Combined siRNA and Small-Molecule Phenotypic Screening Identifies Targets Regulating Rhinovirus Replication in Primary Human Bronchial Epithelial Cells. SLAS Discovery, 2020, 25, 634-645.	1.4	1
1047	Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data. ACS Chemical Biology, 2020, 15, 1424-1444.	1.6	4
1048	The design and development of covalent protein-protein interaction inhibitors for cancer treatment. Journal of Hematology and Oncology, 2020, 13, 26.	6.9	50
1049	IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models. PLoS ONE, 2020, 15, e0229801.	1.1	4
1050	Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins. Frontiers in Chemistry, 2020, 8, 110.	1.8	6
1051	Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?. Journal of Clinical Medicine, 2020, 9, 1892.	1.0	11
1052	Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration. Molecular and Cellular Neurosciences, 2020, 107, 103523.	1.0	16
1053	Exploring different approaches to improve the success of drug discovery and development projects: a review. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	81
1054	Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage. Nutrients, 2020, 12, 1901.	1.7	32
1055	The Surprising Effect of Phenformin on Cutaneous Darkening and Characterization of Its Underlying Mechanism by a Forward Chemical Genetics Approach. International Journal of Molecular Sciences, 2020, 21, 1451.	1.8	4
1056	Synthesis of amideâ€linked benzazolyl isoxazoles adopting green methods and evaluation as antimicrobials. Journal of Heterocyclic Chemistry, 2020, 57, 1882-1892.	1.4	4
1057	Activity-based protein profiling: Recent advances in medicinal chemistry. European Journal of Medicinal Chemistry, 2020, 191, 112151.	2.6	61
1058	Suppression of Drug-Resistant Non-Small-Cell Lung Cancer with Inhibitors Targeting Minichromosomal Maintenance Protein. Journal of Medicinal Chemistry, 2020, 63, 3172-3187.	2.9	11
1059	<i>Cordyceps militaris</i> Exerts Antitumor Effect on Carboplatin-Resistant Ovarian Cancer via Activation of ATF3/TP53 Signaling In Vitro and In Vivo. Natural Product Communications, 2020, 15, 1934578X2090255.	0.2	0
1060	Re-Engineering of Yohimbine's Biological Activity through Ring Distortion: Identification and Structure–Activity Relationships of a New Class of Antiplasmodial Agents. ACS Infectious Diseases, 2020, 6, 159-167.	1.8	20
1061	Green synthesis of 3,4â€disubstituted isoxazolâ€5(4 <i>H</i> )â€ones using ZnO@Fe <sub>3</sub> O <sub>4</sub> core–shell nanocatalyst in water. Applied Organometallic Chemistry, 2020, 34, e5544.	1.7	32

#	Article	IF	CITATIONS
1062	Identification of Psychoplastogenic <i>N</i> , <i>N</i> Dimethylaminoisotryptamine (isoDMT) Analogues through Structure–Activity Relationship Studies. Journal of Medicinal Chemistry, 2020, 63, 1142-1155.	2.9	49
1063	Drug resistance in Giardia: Mechanisms and alternative treatments for Giardiasis. Advances in Parasitology, 2020, 107, 201-282.	1.4	53
1064	High-throughput synthetic rescue for exhaustive characterization of suppressor mutations in human genes. Cellular and Molecular Life Sciences, 2020, 77, 4209-4222.	2.4	2
1065	Predictive models for estimating cytotoxicity on the basis of chemical structures. Bioorganic and Medicinal Chemistry, 2020, 28, 115422.	1.4	16
1066	<p>On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine</p> . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 105-119.	0.4	10
1067	Firstâ€inâ€Human Studies of MW01â€6â€189WH, a Brainâ€Penetrant, Antineuroinflammatory Smallâ€Molecule Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development, 2021, 10, 131-143.	Drug 0.8	8
1068	Extracellular DNA: A Relevant Plant Damage-Associated Molecular Pattern (DAMP) for Crop Protection Against Pests—A Review. Journal of Plant Growth Regulation, 2021, 40, 451-463.	2.8	14
1069	Molecular genomic features associated with <i>inÂvitro</i> response of the NClâ€60 cancer cell line panel to natural products. Molecular Oncology, 2021, 15, 381-406.	2.1	14
1070	Drug screening using shape-based virtual screening and <i>in vitro </i> experimental models of cutaneous Leishmaniasis. Parasitology, 2021, 148, 98-104.	0.7	2
1071	Photoaffinity Labeling and Quantitative Chemical Proteomics Identify $LXR\hat{I}^2$ as the Functional Target of Enhancers of Astrocytic apoE. Cell Chemical Biology, 2021, 28, 148-157.e7.	2.5	12
1072	Design and synthesis of nature-inspired chromenopyrroles as potential modulators of mitochondrial metabolism. Medicinal Chemistry Research, 2021, 30, 635-646.	1.1	3
1073	Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders., 2021, 221, 107749.		29
1074	Exploring the dynamics of novelty production through exaptation: a historical analysis of coal tar-based innovations. Research Policy, 2021, 50, 104171.	3.3	17
1075	Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design. ACS Chemical Biology, 2021, 16, 58-66.	1.6	5
1076	A cell competition–based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. Journal of Biological Chemistry, 2021, 296, 100179.	1.6	6
1077	Image-based profiling for drug discovery: due for a machine-learning upgrade?. Nature Reviews Drug Discovery, 2021, 20, 145-159.	21.5	194
1078	Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen. ACS Medicinal Chemistry Letters, 2021, 12, 99-106.	1.3	3
1079	Phenotypic screening techniques for <i>Cryptosporidium </i> drug discovery. Expert Opinion on Drug Discovery, 2021, 16, 59-74.	2.5	16

#	ARTICLE	IF	CITATIONS
1080	The iPPI-DB initiative: a community-centered database of protein–protein interaction modulators. Bioinformatics, 2021, 37, 89-96.	1.8	24
1081	Pharmacological Target Engagement and Validation. , 2021, , .		0
1082	The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery. RSC Medicinal Chemistry, 2021, 12, 646-665.	1.7	6
1083	Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening. Scientific Reports, 2021, 11, 1439.	1.6	20
1084	A High-Throughput Assay for the Pancreatic Islet Beta-Cell Potassium Channel: Use in the Pharmacological Characterization of Insulin Secretagogues Identified from Phenotypic Screening. Assay and Drug Development Technologies, 2021, 19, 27-37.	0.6	2
1085	Holistic Assessment of Compound Propertiesâ€"In Vitro to In Vivo Pharmacology. , 2021, , .		0
1086	Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries. SLAS Discovery, 2021, 26, 263-280.	1.4	24
1087	Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. Genetics and Molecular Biology, 2021, 44, e20200198.	0.6	3
1088	Adult and Developing Zebrafish as Suitable Models for Cardiac Electrophysiology and Pathology in Research and Industry. Frontiers in Physiology, 2020, 11, 607860.	1.3	16
1089	Chemopreventive Potential of Flavones, Flavonols, and their Glycosides. , 2021, , 97-115.		1
1090	The Concept of Receptor and Molecule Interaction in Drug Discovery and Development., 2021,, 67-102.		3
1091	Online Resource and Tools for the Development of Drugs Against Novel Coronavirus. Methods in Pharmacology and Toxicology, 2021, , 735-759.	0.1	7
1092	Compound Screening., 2021,,.		0
1093	Application of Network Pharmacology Based on Artificial Intelligence Algorithms in Drug Development. , 2021, , 35-73.		2
1094	Drug Discovery in Induced Pluripotent Stem Cell Models. , 2021, , .		0
1095	A quantitative metric for the comparative evaluation of optical clearing protocols for 3D multicellular spheroids. Computational and Structural Biotechnology Journal, 2021, 19, 1233-1243.	1.9	2
1096	The NANOTUMOR consortium – Towards the Tumor Cell Atlas. Biology of the Cell, 2021, 113, 272-280.	0.7	1
1097	Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery. Current Drug Research Reviews, 2021, 13, 101-119.	0.7	12

#	Article	IF	Citations
1098	Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discovery Today, 2021, 26, 511-524.	3.2	136
1099	Fast Nanoliterâ€Scale Cell Assays Using Droplet Microarray–Mass Spectrometry Imaging. Advanced Biology, 2021, 5, e2000279.	1.4	14
1100	Shining a Light on Phenotypic Drug Discovery. Cell Chemical Biology, 2021, 28, 115-117.	2.5	0
1101	Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study. Molecules, 2021, 26, 1977.	1.7	16
1102	Drug screening to identify compounds to act as co-therapies for the treatment of Burkholderia species. PLoS ONE, 2021, 16, e0248119.	1.1	2
1103	Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads. Expert Review of Anti-Infective Therapy, 2021, 19, 1099-1106.	2.0	15
1105	The future of phenotypic drug discovery. Cell Chemical Biology, 2021, 28, 424-430.	2.5	24
1106	N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. ACS Pharmacology and Translational Science, 2021, 4, 980-1000.	2.5	14
1108	An Overview on the Therapeutics of Neglected Infectious Diseasesâ€"Leishmaniasis and Chagas Diseases. Frontiers in Chemistry, 2021, 9, 622286.	1.8	58
1109	Chemoproteomic-enabled phenotypic screening. Cell Chemical Biology, 2021, 28, 371-393.	2.5	20
1111	Clinical Trial in a Dish. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1019-1031.	1.1	21
1112	Beyond Pseudoâ€natural Products: Sequential Ugi/Pictetâ€Spengler Reactions Leading to Steroidal Pyrazinoisoquinolines That Trigger Caspaseâ€Independent Death in HepG2 Cells. ChemMedChem, 2021, 16, 1945-1955.	1.6	3
1113	Late-Stage <sup>18</sup> F/ <sup>19</sup> F Isotopic Exchange for the Synthesis of <sup>18</sup> F-Labeled Sulfamoyl Fluorides. Organic Letters, 2021, 23, 2766-2771.	2.4	15
1114	High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need. Cell Chemical Biology, 2021, 28, 338-355.	2.5	27
1115	Recent advances in identifying protein targets in drug discovery. Cell Chemical Biology, 2021, 28, 394-423.	2.5	69
1117	A Perspective on Synthetic Biology in Drug Discovery and Developmentâ€"Current Impact and Future Opportunities. SLAS Discovery, 2021, 26, 581-603.	1.4	10
1118	Remodelling structure-based drug design using machine learning. Emerging Topics in Life Sciences, 2021, 5, 13-27.	1.1	6
1119	Early Stages of Drug Discovery in an Academic Institution and Involvement of Pharma for Advancing Promising Leads. ACS Infectious Diseases, 2021, 7, 1874-1876.	1.8	1

#	Article	IF	CITATIONS
1120	The evolution of commercial drug delivery technologies. Nature Biomedical Engineering, 2021, 5, 951-967.	11.6	539
1121	Use of artificial intelligence to enhance phenotypic drug discovery. Drug Discovery Today, 2021, 26, 887-901.	3.2	30
1122	Brief Guide: Experimental Strategies for High-Quality Hit Selection from Small-Molecule Screening Campaigns. SLAS Discovery, 2021, 26, 851-854.	1.4	13
1123	Subcellular proteomics. Nature Reviews Methods Primers, 2021, 1, .	11.8	159
1124	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery. ChemMedChem, 2021, 16, 1737-1740.	1.6	7
1125	Construction and Biological Evaluation of Small Libraries Based on the Intermediates within the Total Synthesis of Uvaretin. ChemMedChem, 2021, 16, 1631-1639.	1.6	0
1126	An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. Drug Discovery Today, 2021, 26, 1115-1125.	3.2	3
1127	Drug Target Identification with Machine Learning: How to Choose Negative Examples. International Journal of Molecular Sciences, 2021, 22, 5118.	1.8	6
1128	Safe Polycationic Dendrimers as Potent Oral In Vivo Inhibitors of <i>Mycobacterium tuberculosis</i> A New Therapy to Take Down Tuberculosis. Biomacromolecules, 2021, 22, 2659-2675.	2.6	18
1129	Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. Frontiers in Cellular and Infection Microbiology, 2021, 11, 684515.	1.8	56
1130	Utilizing graph machine learning within drug discovery and development. Briefings in Bioinformatics, 2021, 22, .	3.2	90
1131	Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development. Pharmaceuticals, 2021, 14, 525.	1.7	10
1132	Discovery of K $<$ sub $>$ V $<$ /sub $>$ 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges. Medicinal Research Reviews, 2021, 41, 2423-2473.	5.0	23
1133	Synthesis and Herbicidal Activity of Triketone-Aminopyridines as Potent <i>p</i> h-Hydroxyphenylpyruvate Dioxygenase Inhibitors. Journal of Agricultural and Food Chemistry, 2021, 69, 5734-5745.	2.4	26
1134	In vivo antidiabetic potential of standardized Gymnocarpos decandrus Forssk. Extract. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1129-1135.	0.8	2
1135	Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials. Nature Reviews Drug Discovery, 2021, 20, 611-628.	21.5	192
1136	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. ELife, $2021,10,10$	2.8	15
1137	Systematically Studying the Effect of Small Molecules Interacting with RNA in Cellular and Preclinical Models. ACS Chemical Biology, 2021, 16, 1111-1127.	1.6	10

#	Article	IF	CITATIONS
1138	Droplet microarrays for cell culture: effect of surface properties and nanoliter culture volume on global transcriptomic landscape. Materials Today Bio, 2021, 11, 100112.	2.6	7
1140	Chronic Stress-Induced Depression and Anxiety Priming Modulated by Gut-Brain-Axis Immunity. Frontiers in Immunology, 2021, 12, 670500.	2.2	54
1141	New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?., 2022, 229, 107934.		19
1142	Localization of Organelle Proteins by Isotope Tagging: Current status and potential applications in drug discovery research. Drug Discovery Today: Technologies, 2021, 39, 57-67.	4.0	5
1143	Ring Distortion of Vincamine Leads to the Identification of Re-Engineered Antiplasmodial Agents. ACS Omega, 2021, 6, 20455-20470.	1.6	4
1144	Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells. Cancers, 2021, 13, 3780.	1.7	4
1146	Undeterred by the risk of failure. Nature Biomedical Engineering, 2021, 5, 637-638.	11.6	1
1147	Determination of Ligand Binding Modes in Hydrated Viral Ion Channels to Foster Drug Design and Repositioning. Journal of Chemical Information and Modeling, 2021, 61, 4011-4022.	2.5	10
1148	Phenotypic screening system using three-dimensional (3D) culture models for natural product screening. Journal of Antibiotics, 2021, 74, 660-666.	1.0	3
1149	A CMOS 21 952-Pixel Multi-Modal Cell-Based Biosensor With Four-Point Impedance Sensing for Holistic Cellular Characterization. IEEE Journal of Solid-State Circuits, 2021, 56, 2438-2451.	3.5	10
1150	Manifold medicine: A schema that expands treatment dimensionality. Drug Discovery Today, 2022, 27, 8-16.	3.2	5
1151	An evidence update on the protective mechanism of tangeretin against neuroinflammation based on network pharmacology prediction and transcriptomic analysis. European Journal of Pharmacology, 2021, 906, 174094.	1.7	7
1152	High-content approaches to anthelmintic drug screening. Trends in Parasitology, 2021, 37, 780-789.	1.5	14
1153	Drug repurposing: Iron in the fire for older drugs. Biomedicine and Pharmacotherapy, 2021, 141, 111638.	2.5	16
1154	Mind the Gaps: How Organization Design Shapes the Sourcing of Inventions. Organization Science, 2022, 33, 1319-1339.	3.0	10
1155	Combining Automated Organoid Workflows with Artificial Intelligenceâ€Based Analyses: Opportunities to Build a New Generation of Interdisciplinary Highâ€Throughput Screens for Parkinson's Disease and Beyond. Movement Disorders, 2021, 36, 2745-2762.	2.2	10
1156	Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPAR $\hat{I}^3$ with potential anti-diabetic efficacy. European Journal of Medicinal Chemistry, 2021, 222, 113542.	2.6	4
1157	Pathways to Treatment Development. , 2022, , 226-239.		0

#	Article	IF	CITATIONS
1158	The pursuit of mechanism of action: uncovering drug complexity in TB drug discovery. RSC Chemical Biology, 2021, 2, 423-440.	2.0	9
1159	Translational research—from basic science to an approved therapeutic—an overview. , 2021, , 663-681.		1
1160	Exploring gene knockout strategies to identify potential drug targets using genome-scale metabolic models. Scientific Reports, 2021, 11, 213.	1.6	15
1161	Key Aspects for Achieving Hits by Virtual Screening Studies. Engineering Materials, 2021, , 455-487.	0.3	3
1162	High-throughput organ-on-chip platform with integrated programmable fluid flow and real-time sensing for complex tissue models in drug development workflows. Lab on A Chip, 2021, 21, 1454-1474.	3.1	107
1163	Highâ€Throughput RTâ€PCR for Smallâ€Molecule Screening Assays. Current Protocols in Chemical Biology, 2012, 4, 49-63.	1.7	15
1166	A High Content Screening Approach to Identify Molecules Neuroprotective for Photoreceptor Cells. Advances in Experimental Medicine and Biology, 2014, 801, 773-781.	0.8	15
1167	Small-Molecule Library Screening by Docking with PyRx. Methods in Molecular Biology, 2015, 1263, 243-250.	0.4	1,807
1168	Label-Free Cell Phenotypic Identification of Active Compounds in Traditional Chinese Medicines. Methods in Pharmacology and Toxicology, 2015, , 233-252.	0.1	2
1169	Profiling of Small Molecules by Chemical Proteomics. Methods in Molecular Biology, 2016, 1394, 211-218.	0.4	16
1170	Challenges and Opportunities in Enabling High-Throughput, Miniaturized High Content Screening. Methods in Molecular Biology, 2018, 1683, 165-191.	0.4	6
1171	A Drosophila Based Cancer Drug Discovery Framework. Advances in Experimental Medicine and Biology, 2019, 1167, 237-248.	0.8	8
1172	The Efficiency of Multi-target Drugs: A Network Approach. Human Perspectives in Health Sciences and Technology, 2020, , 63-75.	0.2	2
1173	Discovery and Development of RRx-001, a Novel Nitric Oxide and ROS Mediated Epigenetic Modulator., 2015, , 259-277.		2
1174	Introduction to the Global Scenario of Marine Sponge Research. , 2016, , 1-23.		1
1175	Network Pharmacology to Aid the Drug Discovery Process. , 2012, , 161-172.		3
1176	Structures, Limitations, and Pitfalls. , 2016, , 3-14.		2
1177	A perspective on the discovery of selected compounds with anthelmintic activity against the barber's pole wormâ€"Where to from here?. Advances in Parasitology, 2020, 108, 1-45.	1.4	17

#	Article	IF	CITATIONS
1178	Novel triazine dimers with potent antitrypanosomal activity. European Journal of Medicinal Chemistry, 2018, 143, 306-319.	2.6	16
1179	Multifunctional compounds lithium chloride and methylene Blue attenuate the negative effects of diisopropylfluorophosphate on axonal transport in rat cortical neurons. Toxicology, 2020, 431, 152379.	2.0	7
1181	Advanced identification of global bioactivity hotspots via screening of the metabolic fingerprint of entire ecosystems. Scientific Reports, 2020, 10, 1319.	1.6	17
1182	Drug Discovery Approaches for Rare Neuromuscular Diseases. RSC Drug Discovery Series, 2014, , 257-343.	0.2	3
1183	The Pursuit of Novel Anti-leishmanial Agents by High-throughput Screening (HTS) of Chemical Libraries. RSC Drug Discovery Series, 2017, , 77-100.	0.2	1
1184	Targeting RNA structures in diseases with small molecules. Essays in Biochemistry, 2020, 64, 955-966.	2.1	22
1185	Antibacterial medicinal chemistry – what can we design for?. Expert Opinion on Drug Discovery, 2020, 15, 1005-1013.	2.5	4
1194	Recent advances in phenotypic drug discovery. F1000Research, 2020, 9, 944.	0.8	37
1195	Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V Rett syndrome mouse model. F1000Research, 2016, 5, 2269.	0.8	38
1196	Resonant Waveguide Grating Biosensors for Cell Biology and Drug Discovery. , 2012, , .		3
1197	Representing high throughput expression profiles via perturbation barcodes reveals compound targets. PLoS Computational Biology, 2017, 13, e1005335.	1.5	24
1198	Systematic Drug Repositioning Based on Clinical Side-Effects. PLoS ONE, 2011, 6, e28025.	1.1	223
1199	Formalization, Annotation and Analysis of Diverse Drug and Probe Screening Assay Datasets Using the BioAssay Ontology (BAO). PLoS ONE, 2012, 7, e49198.	1.1	49
1200	In Vitro and In Vivo Activities of Ruthenium(II) Phosphine/Diimine/Picolinate Complexes (SCAR) against Mycobacterium tuberculosis. PLoS ONE, 2013, 8, e64242.	1.1	30
1201	High Content Screening as High Quality Assay for Biological Evaluation of Photosensitizers In Vitro. PLoS ONE, 2013, 8, e70653.	1.1	12
1202	Discovery of Potent Broad Spectrum Antivirals Derived from Marine Actinobacteria. PLoS ONE, 2013, 8, e82318.	1.1	79
1203	New Small Molecules Targeting Apoptosis and Cell Viability in Osteosarcoma. PLoS ONE, 2015, 10, e0129058.	1.1	15
1204	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning. PLoS ONE, 2015, 10, e0135556.	1.1	81

#	Article	IF	CITATIONS
1205	When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis. PLoS ONE, 2016, 11, e0147215.	1.1	202
1206	Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis. PLoS ONE, 2016, 11, e0149439.	1.1	17
1207	Timelines of translational science: From technology initiation to FDA approval. PLoS ONE, 2017, 12, e0177371.	1.1	43
1208	Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. PLoS ONE, 2017, 12, e0189380.	1.1	50
1209	Primary cell-based phenotypic assays to pharmacologically and genetically study fibrotic diseases in vitro. Journal of Biological Methods, 2019, 6, e115.	1.0	16
1210	Reverse Pharmacology: Fast Track Path of Drug Discovery. Pharmacy & Pharmacology International Journal, 2016, 4, .	0.1	3
1211	Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes. Oncotarget, 2019, 10, 3472-3490.	0.8	23
1212	A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras. Oncotarget, 2015, 6, 5382-5411.	0.8	11
1213	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget, 2015, 6, 38458-38468.	0.8	19
1214	Human Disease and Drug Pharmacology, Complex as Real Life. Current Medicinal Chemistry, 2013, 20, 1623-1634.	1.2	33
1215	Structure and Function of Prokaryotic UDP-Glucose Pyrophosphorylase, A Drug Target Candidate. Current Medicinal Chemistry, 2015, 22, 1687-1697.	1.2	34
1216	Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets. Current Medicinal Chemistry, 2015, 22, 3133-3161.	1.2	22
1217	Computational Drug Repurposing: Current Trends. Current Medicinal Chemistry, 2019, 26, 5389-5409.	1.2	52
1218	Recent Advances in Drug Repurposing for Parkinson's Disease. Current Medicinal Chemistry, 2019, 26, 5340-5362.	1.2	9
1219	Small molecule Screening at Helmholtz Zentrum Mþnchen – From Biology to Molecules. Combinatorial Chemistry and High Throughput Screening, 2014, 17, 266-271.	0.6	5
1220	High Throughput Screening for Colorectal Cancer Specific Compounds. Combinatorial Chemistry and High Throughput Screening, 2016, 19, 180-188.	0.6	3
1221	Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances. Combinatorial Chemistry and High Throughput Screening, 2019, 22, 509-520.	0.6	6
1222	Novel Therapeutic Potential of Mitogen-Activated Protein Kinase Activated Protein Kinase 2 (MK2) in Chronic Airway Inflammatory Disorders. Current Drug Targets, 2019, 20, 367-379.	1.0	18

#	Article	IF	CITATIONS
1223	Systems Biology Approaches to a Rational Drug Discovery Paradigm. Current Topics in Medicinal Chemistry, 2015, 16, 1009-1025.	1.0	25
1224	Identifying Small Molecules which Inhibit Autophagy: a Phenotypic Screen Using Image-Based High-Content Cell Analysis. Current Chemical Genomics and Translational Medicine, 2014, 8, 3-15.	4.3	30
1225	Zebrafish-Based Screening Models for the Identification of Anti-Metastatic Drugs. Molecules, 2020, 25, 2407.	1.7	17
1226	The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development. Pharmaceutics, 2021, 13, 44.	2.0	17
1227	Perspective Studies on Novel Anticancer Drugs from Natural Origin: A Comprehensive Review. International Journal of Pharmacology, 2014, 10, 90-108.	0.1	7
1228	Drug Discovery Processes to Drug Targeting Mechanisms. International Journal of Pharmacology, 2017, 13, 773-784.	0.1	2
1229	Virtual target screening to rapidly identify potential protein targets of natural products in drug discovery. AIMS Molecular Science, 2014, 1, 81-98.	0.3	1
1230	A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity. ELife, 2020, 9, .	2.8	16
1231	Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 4079-4088.	3.9	6
1232	An overview of metal-free synthetic routes to isoxazoles: the privileged scaffold. RSC Advances, 2021, 11, 32680-32705.	1.7	28
1233	Marine Biodiscovery in a Changing World. Progress in the Chemistry of Organic Natural Products, 2021, 116, 1-36.	0.8	4
1234	Human Genomics and Drug Development. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a039230.	2.9	16
1235	Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy. Frontiers in Pharmacology, 2021, 12, 730257.	1.6	42
1238	Exposure-response modeling improves selection of radiation and radiosensitizer combinations. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 49, 167.	0.8	2
1239	Opening Up but Staying Local: Insights from Partnership Formations between Established and Startup Firms. SSRN Electronic Journal, 0, , .	0.4	0
1240	Tuberculosis Drug Discovery: Target Identification and Validation. , 2012, , 53-84.		0
1241	Creating Decision Trees to Assess Cost-Effectiveness in Clinical Research. Journal of Biometrics & Biostatistics, 2012, 01, .	4.0	2
1244	Novel New Drug Approvals in 2011: A Succinct Analysis of Drug Discovery Trends in the United States. International Journal of Pharmaceutical Sciences and Nanotechnology, 2012, 5, 1661-1665.	0.0	3

#	Article	IF	CITATIONS
1245	Biosensors: On the Origin of Label-Free Cell Phenotypic Profiles of Drug-Target Interactions. Journal of Biochips $\&$ Tissue Chips, 2013, 03, .	0.2	1
1246	Design and Implementation of an Interdisciplinary Elective Course in Drug Discovery, Development, and Commercialization. Innovations in Pharmacy, 2013, 4, .	0.2	0
1247	New Drugs of 2012: A Concise Overview of the NMEs and Trends for Innovative Brand Market in the United States. International Journal of Pharmaceutical Sciences and Nanotechnology, 2013, 6, 2009-2013.	0.0	3
1248	Background of Pharmacologic Modeling. , 2014, , 1-20.		O
1249	Small Molecules that Rescue F508del CFTR as Cystic Fibrosis Therapies. RSC Drug Discovery Series, 2014, , 230-254.	0.2	0
1250	Kidney on a Chip. RSC Nanoscience and Nanotechnology, 2014, , 19-39.	0.2	1
1251	Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?. Perspectives on Sustainable Growth, 2015, , 39-68.	0.3	1
1252	Epigenetic Drug Discovery. NATO Science for Peace and Security Series A: Chemistry and Biology, 2015, , 27-40.	0.5	0
1253	Progress in Targeting Epigenetic Readers. RSC Drug Discovery Series, 2015, , 192-229.	0.2	0
1254	Motility Contrast Imaging and Tissue Dynamics Spectroscopy. , 2015, , 1189-1205.		0
1255	Chapter 13. The Business Case for Green Chemistry in Drug Discovery. RSC Drug Discovery Series, 2015, , 280-313.	0.2	1
1256	Targeting apoptosis is the major battle field for killing cancers. World Journal of Translational Medicine, 2015, 4, 69.	3.5	0
1257	Genetic Strategies for Identifying New Drug Targets. , 0, , 493-509.		0
1259	The Use of a Chemical Biology in the Development of a Novel MEK1/2 Inhibitor. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2016, 74, 462-468.	0.0	0
1262	Biological Targets., 2016,, 33-49.		0
1263	Anticancer Activity of Salvia miltiorrhiza and Its Secondary Metabolites. , 2017, , 179-207.		1
1264	Trends in Bioprobe Research. , 2017, , 1-10.		0
1265	6 High-content imaging for photosensitizer screening. Series in Cellular and Clinical Imaging, 2017, , 103-116.	0.2	0

#	Article	IF	CITATIONS
1267	Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Advancing Cardiovascular Medicine. , 2018, , 87-93.		0
1268	Cheminformatics Tools for Analyzing and Designing Optimized Small Molecule Collections and Libraries. SSRN Electronic Journal, 0, , .	0.4	0
1269	Discovery Scienceã«éã•ã,‰ã,Œã∮. Kagaku To Seibutsu, 2018, 56, 210-216.	0.0	0
1271	Traditional Chinese Medicine and Clinical Pharmacology. , 2019, , 1-28.		O
1272	A Strength-Weaknesses-Opportunities-Threats (SWOT) Analysis of Cheminformatics in Natural Product Research. Progress in the Chemistry of Organic Natural Products, 2019, 110, 239-271.	0.8	3
1273	From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies. Methods in Molecular Biology, 2019, 2049, 419-444.	0.4	2
1274	Interrogating Cardiovascular Genetics in Zebrafish. Cardiac and Vascular Biology, 2019, , 313-339.	0.2	0
1280	Identification of Curcuma aromatica growing in Vietnam and its potential anticancer components. Y Hoc Thanh Pho Ho Chi Minh, 2017, 3, 12-18.	0.1	1
1281	Identification of C. elegans lipid lowering constituents form chaga by correlation of 1H NMR spectra with phenotypic screening. Planta Medica, $2019, 85, .$	0.7	0
1282	Chemopreventive Potential of Flavones, Flavonols, and their Glycosides. , 2020, , 1-19.		2
1283	Public–Private Partnerships to Advance Phenotypic Drug Discovery. RSC Drug Discovery Series, 2020, , 118-139.	0.2	0
1285	Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia. RSC Drug Discovery Series, 2020, , 175-197.	0.2	1
1286	Fraction Libraries and Genetics as Tools for Natural Product Research: Focus on Decalin-Containing Compounds., 2020,, 375-409.		0
1287	ADMET analysis of phyto-components of Syzygium cumini seeds and Allium cepa peels. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	4
1288	MNBDR: A Module Network Based Method for Drug Repositioning. Genes, 2021, 12, 25.	1.0	6
1289	Drug discovery. , 2022, , 563-572.		1
1290	Connecting chemistry and biology through molecular descriptors. Current Opinion in Chemical Biology, 2022, 66, 102090.	2.8	24
1292	Antibody-based Phenotypic Screening – the Discovery of Oleclumab (MEDI9447). RSC Drug Discovery Series, 2020, , 160-174.	0.2	0

#	Article	IF	CITATIONS
1293	Traditional Chinese Medicine and Clinical Pharmacology. , 2020, , 1-29.		0
1294	Phenotypic Drug Discovery: History, Evolution, Future. RSC Drug Discovery Series, 2020, , 1-19.	0.2	4
1295	Precious Microorganisms as Productive Resources: Marine-Derived Microorganisms and Combined-Culture., 2020,, 430-456.		1
1296	Why an <i>In Vivo</i> Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers. RSC Drug Discovery Series, 2020, , 217-232.	0.2	0
1297	Mol2Image: Improved Conditional Flow Models for Molecule to Image Synthesis. , 2021, , .		9
1299	Kidney dysfunction requiring dialysis is a heterogeneous syndrome: we should treat it like one. Current Opinion in Nephrology and Hypertension, 2022, 31, 92-99.	1.0	6
1300	Identification and Development of Therapeutics for COVID-19. MSystems, 2021, 6, e0023321.	1.7	20
1301	Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?. Current Alzheimer Research, 2013, 10, 21-9.	0.7	28
1302	Production of a compound against methicillin resistant Staphylococcus aureus (MRSA) from Streptomyces rubrolavendulae ICN3 & its evaluation in zebrafish embryos. Indian Journal of Medical Research, 2014, 139, 913-20.	0.4	6
1303	Translating Stem Cell Biology Into Drug Discovery. Drug Target Review, 2016, 3, 34-38.	1.0	O
1304	Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development. Handbook of Experimental Pharmacology, 2021, 271, 197-220.	0.9	5
1305	Frontiers in antibiotic alternatives for <i>Clostridioides difficile </i> infection. World Journal of Gastroenterology, 2021, 27, 7210-7232.	1.4	5
1306	Improving Translational Paradigms in Drug Discovery and Development. Current Protocols, 2021, 1, e273.	1.3	3
1307	Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 815-826.	1.2	1
1308	Developing nociceptor-selective treatments for acute and chronic pain. Science Translational Medicine, 2021, 13, eabj9837.	5.8	22
1309	Machine Learning and Deep Learning Strategies in Drug Repositioning. Current Bioinformatics, 2022, 17, 217-237.	0.7	2
1310	Large-Scale Functional Genomics Screen to Identify Modulators of Human $\hat{l}^2$ -Cell Insulin Secretion. Biomedicines, 2022, 10, 103.	1.4	11
1311	Computer-aided structural optimization, synthesis, evaluation of the antimicrobial and cytotoxic activity of some pyrazoline derivatives. Y Hoc Thanh Pho Ho Chi Minh, 2021, 6, 33-39.	0.1	0

#	Article	IF	CITATIONS
1312	DDIT: An Online Predictor for Multiple Clinical Phenotypic Drug-Disease Associations. Frontiers in Pharmacology, 2021, 12, 772026.	1.6	1
1313	Discovery and Development of the Quininib Series of Ocular Drugs. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 33-42.	0.6	0
1314	Modern Approaches in the Discovery and Development of Plant-Based Natural Products and Their Analogues as Potential Therapeutic Agents. Molecules, 2022, 27, 349.	1.7	128
1315	Deep Learning-Based Morphological Classification of Endoplasmic Reticulum Under Stress. Frontiers in Cell and Developmental Biology, 2021, 9, 767866.	1.8	6
1316	Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropy. RSC Drug Discovery Series, 2022, , 196-220.	0.2	1
1317	Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase. Journal of Medicinal Chemistry, 2022, 65, 2471-2496.	2.9	5
1318	Small-Molecule Lead-Finding Trends across the Roche and Genentech Research Organizations. Journal of Medicinal Chemistry, 2022, 65, 3606-3615.	2.9	11
1319	The translational challenge in Chagas disease drug development. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	0.8	21
1321	Computational prediction of drug phenotypiceffects based on substructure-phenotype associations. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, PP, 1-1.	1.9	0
1322	Discovery of the First-in-Class Mek Inhibitor Trametinib (Trade Name: Mekinist) and Other Molecular Targeting Agents by "Rb-Reactivator Screening― SSRN Electronic Journal, 0, , .	0.4	0
1323	Induction of Liver Size Reduction in Zebrafish Larvae by the Emerging Synthetic Cannabinoid 4F-MDMB-BINACA and Its Impact on Drug Metabolism. Molecules, 2022, 27, 1290.	1.7	5
1324	Recent Advances in Divergent Synthetic Strategies for Indole-Based Natural Product Libraries. Molecules, 2022, 27, 2171.	1.7	5
1325	The emerging role of mass spectrometry-based proteomics in drug discovery. Nature Reviews Drug Discovery, 2022, 21, 637-654.	21.5	110
1327	Strategic, feasibility, economic, and cultural aspects of phase 0 approaches. Clinical and Translational Science, 2022, 15, 1355-1379.	1.5	6
1328	A Mini-Review of the Anticancer Properties of Cryptotanshinone: A Quinoid Diterpene Extracted From the Root of Salvia miotiorrhiza Bunge. Frontiers in Drug Discovery, 2022, 2, .	1.1	2
1329	In silico Drug Screening Approach Using L1000-Based Connectivity Map and Its Application to COVID-19. Frontiers in Cardiovascular Medicine, 2022, 9, 842641.	1.1	5
1330	Discovery and Optimization of 6-(1-Substituted pyrrole-2-yl)- <i>s</i> -triazine Containing Compounds as Antibacterial Agents. ACS Infectious Diseases, 2022, 8, 757-767.	1.8	6
1331	Why medicines work. , 2022, 238, 108175.		1

#	Article	IF	CITATIONS
1332	In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach. Pharmaceutics, 2022, 14, 59.	2.0	12
1333	Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach. International Journal of Molecular Sciences, 2021, 22, 13259.	1.8	30
1334	Stingray Venom Proteins: Mechanisms of Action Revealed Using a Novel Network Pharmacology Approach. Marine Drugs, 2022, 20, 27.	2.2	6
1335	An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduction and Targeted Therapy, 2021, 6, 423.	7.1	21
1336	The importance of drug target selection capability for new drug innovation: definition, fostering process, and interaction with organizational management. Prometheus, 2020, 36, .	0.2	0
1337	Antituberculosis Drug Repurposing: A New Hope for Tackling Multi-Challenging TB in Timely Manner. , $0, , .$		1
1343	Integrative oncology drug discovery accompanied by preclinical translational research as prerequisite for clinical development. Chinese Clinical Oncology, 2014, 3, 15.	0.4	4
1344	Accelerating reaction generality and mechanistic insight through additive mapping. Science, 2022, 376, 532-539.	6.0	61
1345	DRUG-seq Provides Unbiased Biological Activity Readouts for Neuroscience Drug Discovery. ACS Chemical Biology, 2022, 17, 1401-1414.	1.6	7
1348	GlyNet: a multi-task neural network for predicting protein–glycan interactions. Chemical Science, 2022, 13, 6669-6686.	3.7	7
1349	Target Identification Approaches in Drug Discovery. , 2022, , 41-59.		2
1350	Compounds co-targeting kinases in axon regulatory pathways promote regeneration and behavioral recovery after spinal cord injury in mice. Experimental Neurology, 2022, 355, 114117.	2.0	6
1351	Predicting target–ligand interactions with graph convolutional networks for interpretable pharmaceutical discovery. Scientific Reports, 2022, 12, 8434.	1.6	4
1352	Beyond pharmaceuticals: Fit-for-purpose new approach methodologies for environmental cardiotoxicity testing. ALTEX: Alternatives To Animal Experimentation, 0, , .	0.9	1
1353	Phenotypic drug discovery: recent successes, lessons learned and new directions. Nature Reviews Drug Discovery, 2022, 21, 899-914.	21.5	81
1354	Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nature Reviews Cardiology, 2022, 19, 751-764.	6.1	29
1355	Physiologic Targets and Modes of Action for CBL0137, a Lead for Human African Trypanosomiasis Drug Development. Molecular Pharmacology, 2022, 102, 1-16.	1.0	2
1357	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. ACS Chemical Biology, 2022, 17, 1876-1889.	1.6	11

#	Article	IF	CITATIONS
1358	Recent Advances in Cancer Drug Discovery Through the Use of Phenotypic Reporter Systems, Connectivity Mapping, and Pooled CRISPR Screening. Frontiers in Pharmacology, 0, 13, .	1.6	4
1359	Coding recognition of the dose–effect interdependence of small biomolecules encrypted on paired chromatographic-based microassay arrays. Analytical and Bioanalytical Chemistry, 2022, 414, 5991-6001.	1.9	0
1361	Zebrafish Larvae Behavior Models as a Tool for Drug Screenings and Pre-Clinical Trials: A Review. International Journal of Molecular Sciences, 2022, 23, 6647.	1.8	38
1362	"RB-reactivator screening―as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). , 2022, 236, 108234.		4
1363	Mechanistic insights on cytotoxicity of <scp>KOLR</scp> , Cinnamomum pauciflorum Nees leaf derived active ingredient, by targeting signaling complexes of phosphodiesterase <scp>3B</scp> and rap guanine nucleotide exchange factor 3. Phytotherapy Research, 0, , .	2.8	0
1364	GC-MS Profiling of Phytobioconstituents Present in Andrographis paniculata (Burm.f.) Nees Extract and Pharmacokinetic and Toxicity Properties by ADME/Tox Analysis. Asian Journal of Chemistry, 2022, 34, 2167-2172.	0.1	0
1365	Machine Learning and Artificial Intelligence: A Paradigm Shift in Big Data-Driven Drug Design and Discovery. Current Topics in Medicinal Chemistry, 2022, 22, 1692-1727.	1.0	8
1367	Replenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage Plasmodium falciparum, using a nano luciferase reporter read-out. SLAS Discovery, 2022, 27, 337-348.	1.4	5
1369	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. European Journal of Medicinal Chemistry, 2022, 243, 114742.	2.6	1
1370	General Strategies for Rational Design and Discovery of Multitarget Drugs., 2022,, 677-736.		0
1371	Polypharmacology in Old Drug Rediscovery: Drug Repurposing. , 2022, , 535-592.		2
1372	Polypharmacology in Drug Design and Discovery—Basis for Rational Design of Multitarget Drugs. , 2022, , 397-533.		1
1373	Zebrafish models for cancer research. Okayama Igakkai Zasshi, 2022, 134, 76-78.	0.0	0
1374	On drug discovery against infectious diseases and academic medicinal chemistry contributions. Beilstein Journal of Organic Chemistry, 0, 18, 1355-1378.	1.3	0
1375	Deep Learning in Cell Image Analysis. , 2022, 2022, .		8
1376	Drug repositioning: A bibliometric analysis. Frontiers in Pharmacology, 0, 13, .	1.6	7
1377	Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present). Expert Opinion on Therapeutic Patents, 2022, 32, 1097-1122.	2.4	4
1378	Deep-learning analysis of micropattern-based organoids enables high-throughput drug screening of Huntington's disease models. Cell Reports Methods, 2022, 2, 100297.	1.4	8

#	Article	IF	Citations
1379	Novel 5-Nitrofuran-Tagged Imidazo-Fused Azines and Azoles Amenable by the Groebke–Blackburn–Bienaymé Multicomponent Reaction: Activity Profile against ESKAPE Pathogens and Mycobacteria. Biomedicines, 2022, 10, 2203.	1.4	2
1380	A convenient synthesis of (3S,3aR,5R,7aS,8S)-Hexahydro-4H-3,5-methanofuro[2,3-b]pyran-8-ol, a high-affinity nonpeptidyl ligand for highly potent HIV-1 protease inhibitors. Tetrahedron Letters, 2022, , 154161.	0.7	0
1381	Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nature Reviews Drug Discovery, 2022, 21, 915-931.	21.5	28
1382	Proteome Integral Solubility Alteration (PISA) for High-Throughput Ligand Target Deconvolution with Increased Statistical Significance and Reduced Sample Amount. Methods in Molecular Biology, 2023, , 91-106.	0.4	9
1383	Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury. Biomedicines, 2022, 10, 2449.	1.4	4
1384	Chemically induced phenotypes during the blood stage development of Plasmodium falciparum as indicators of the drug mode of action. Frontiers in Drug Discovery, 0, 2, .	1.1	1
1385	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules, 2022, 12, 1590.	1.8	6
1388	Phenotype-based drug screening: An in vivo strategy to classify and identify the chemical compounds modulating zebrafish M-cell regeneration. Frontiers in Molecular Biosciences, 0, 9, .	1.6	0
1389	Possibility Extent and Possible Alternatives Preorder Type-2 Fuzzy Analytical Hierarchy Process (PE&PAP-AHP) to improve pharmaceutical R&D productivity. Applied Soft Computing Journal, 2022, 131, 109770.	4.1	0
1391	Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2022, 244, 114867.	2.6	1
1392	Evidence-based support for phenotypic drug discovery in acute myeloid leukemia. Drug Discovery Today, 2022, 27, 103407.	3.2	1
1393	Label-free target protein characterization for small molecule drugs: recent advances in methods and applications. Journal of Pharmaceutical and Biomedical Analysis, 2023, 223, 115107.	1.4	6
1394	Phenotypic screening identifies hydroxypyridone anti-fungals as novel medicines for the prevention of hypertrophic scars. European Journal of Pharmacology, 2022, 937, 175374.	1.7	2
1395	Identification of a novel <scp>ALDH1A3</scp> â€selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinityâ€based drug target discovery. Chemical Biology and Drug Design, 0, , .	1.5	1
1396	Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction. Cancers, 2022, 14, 5604.	1.7	0
1397	Small bioactive molecules designed to be probes as baits "fishing out" cellular targets: Finding the fish in the proteome sea. Chinese Journal of Analytical Chemistry, 2023, 51, 100196.	0.9	0
1398	The Application of Highâ€Throughput Approaches in Identifying Novel Therapeutic Targets and Agents to Treat Diabetes. Advanced Biology, 2023, 7, .	1.4	3
1399	Phenotypic screening-based drug discovery of furan-2-carboxylic acid derivatives for the amelioration of type 2 diabetes mellitus (T2DM). European Journal of Medicinal Chemistry, 2023, 246, 114994.	2.6	1

#	Article	IF	CITATIONS
1400	Cell morphology-guided <i>de novo</i> hit design by conditioning GANs on phenotypic image features. , 2023, 2, 91-102.		4
1401	Original end-to-end smart diagnosis framework of systematic critical quality attributes meets FDA standards of phytomedicine by biosensor and multi-information fusion coupled with Al algorithm. Green Chemistry, 0, , .	4.6	0
1402	FingerDTA: A Fingerprint-Embedding Framework for Drug-Target Binding Affinity Prediction. Big Data Mining and Analytics, 2023, 6, 1-10.	7.5	7
1403	Proteome Integral Solubility Alteration (PISA) Assay in Mammalian Cells for Deep, High-Confidence, and High-Throughput Target Deconvolution. Bio-protocol, 2022, 12, .	0.2	2
1404	Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer. JCI Insight, 2022, 7, .	2.3	8
1405	A Critical Review of Zebrafish Neurological Disease Modelsâ^'2. Application: Functional and Neuroanatomical Phenotyping Strategies and Chemical Screens. , 2023, 2, .		3
1406	The Global Research Trend in Electrochemical Microfluidic Technology: A Bibliometric Review. Chemosensors, 2023, 11, 14.	1.8	2
1407	Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease. PLoS ONE, 2022, 17, e0277646.	1.1	3
1408	FragDPI: a novel drug-protein interaction prediction model based on fragment understanding and unified coding. Frontiers of Computer Science, 2023, 17, .	1.6	3
1409	Brief considerations on targeting RNA with small molecules. Faculty Reviews, $0,11,.$	1.7	3
1411	Discovery of Novel Polycyclic Phloroglucinols via an Improved One-Pot Method. ACS Omega, 2022, 7, 47174-47182.	1.6	0
1412	Stellettin B Sensitizes Glioblastoma to DNAâ€Damaging Treatments by Suppressing Pl3Kâ€Mediated Homologous Recombination Repair. Advanced Science, 2023, 10, .	5.6	6
1413	A statistical framework for high-content phenotypic profiling using cellular feature distributions. Communications Biology, 2022, 5, .	2.0	1
1414	Phenotype-based screening rediscovered benzopyran-embedded microtubule inhibitors as anti-neuroinflammatory agents by modulating the tubulin–p65 interaction. Experimental and Molecular Medicine, 2022, 54, 2200-2209.	3.2	1
1415	Deep learning in image-based phenotypic drug discovery. Trends in Cell Biology, 2023, 33, 538-554.	3.6	14
1416	DeepNoise: Signal and Noise Disentanglement Based on Classifying Fluorescent Microscopy Images via Deep Learning. Genomics, Proteomics and Bioinformatics, 2022, 20, 989-1001.	3.0	2
1417	Pharmacological modulation of conditioned fear in the fear-potentiated startle test: a systematic review and meta-analysis of animal studies. Psychopharmacology, 2023, 240, 2361-2401.	1.5	4
1418	In Silico Drug Repurposing: An Effective Tool to Accelerate the Drug Discovery Process. , 0, , .		0

#	Article	IF	CITATIONS
1419	Advances of the Target-Based and Phenotypic Screenings and Strategies in Drug Discovery. , 0, , 2.		3
1420	Virtual screening of phytochemicals for drug discovery. , 2023, , 149-179.		1
1421	Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: A comprehensive review. Frontiers in Cellular and Infection Microbiology, $0,13,.$	1.8	14
1422	Computational Prediction of the Phenotypic Effect of Flavonoids on Adiponectin Biosynthesis. Journal of Chemical Information and Modeling, 2023, 63, 856-869.	2.5	2
1423	Drug Repurposing for Hematological Malignancies. , 2023, , 217-252.		0
1424	Cell painting transfer increases screening hit rate. Biological Imaging, 2023, 3, .	1.0	0
1425	High throughput assay for compounds that boost BDNF expression in neurons. SLAS Discovery, 2023, 28, 88-94.	1.4	1
1426	Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. Journal of Biomedical Science, 2023, 30, .	2.6	5
1427	Industrializing Al/ML during the end-to-end drug discovery process. Current Opinion in Structural Biology, 2023, 79, 102528.	2.6	7
1428	Screening for small molecule inhibitors of SAH nucleosidase using an SAH riboswitch. Analytical Biochemistry, 2023, 666, 115047.	1.1	1
1430	Advances in application and innovation of microfluidic platforms for pharmaceutical analysis. TrAC - Trends in Analytical Chemistry, 2023, 160, 116951.	5.8	5
1431	Proteomeâ€Wide Fragmentâ€Based Ligand and Target Discovery. Israel Journal of Chemistry, 2023, 63, .	1.0	1
1432	Prediction of drug protein interactions based on variable scale characteristic pyramid convolution network. Methods, 2023, 211, 42-47.	1.9	0
1434	Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science. Trends in Parasitology, 2023, 39, 260-271.	1.5	6
1437	Drug discovery processes: When and where the rubber meets the road., 2023,, 339-415.		1
1438	Commentary on Bioassay: a pharmacological endeavour by Jacques M. van Rossum and J.Th.A. Hurkmans. , 2023, , 131-136.		0
1439	Zebrafish in Drug Discovery: Safety Assessment. , 2022, , 1-21.		0
1440	Reference compounds for characterizing cellular injury in high-content cellular morphology assays. Nature Communications, 2023, 14, .	5.8	4

#	Article	IF	CITATIONS
1441	Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties. ACS Medicinal Chemistry Letters, 2023, 14, 350-361.	1.3	1
1442	Reverse tracking from drug-induced transcriptomes through multilayer molecular networks reveals hidden drug targets. Computers in Biology and Medicine, 2023, 158, 106881.	3.9	0
1443	Cell-Based Assays for Neurotoxin Studies. , 2014, , 1-22.		0
1444	Cell-Based Assays for Neurotoxins. , 2014, , 1-21.		O
1445	A comprehensive review on potential candidates for the treatment of chagas disease. Chemical Biology and Drug Design, 2023, 102, 587-605.	1.5	1
1446	Strategies for drug repurposing. , 2023, , 117-128.		0
1447	What was old is new again: Phenotypic screening of a unique fungal library yields pyridoxatin, a promising lead against extensively resistant Acinetobacter baumannii (AB5075). Phytochemistry Letters, 2023, 55, 88-96.	0.6	0
1455	Role of Bioinformatics in Drug Design and Discovery. , 2023, , 1-33.		O
1456	In Silico Pharmacology and Drug Repurposing Approaches. , 2023, , 253-281.		0
1464	Marine Natural Products Targeting Tumor Microenvironment. , 2023, , 35-58.		0
1466	Target-Based Screening for Lead Discovery. , 2023, , 141-173.		0
1470	Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities. Cancer Chemotherapy and Pharmacology, 2023, 92, 241-251.	1.1	1
1481	Computer vision meets microfluidics: a label-free method for high-throughput cell analysis. Microsystems and Nanoengineering, 2023, 9, .	3.4	7
1483	RxRx1: A Dataset for Evaluating Experimental Batch Correction Methods. , 2023, , .		8
1484	Phospholipases as therapeutic targets: Systems biology and bioinformatics approaches. , 2023, , 359-374.		0
1486	Deep Mining of Complex Antibody Phage Pools. Methods in Molecular Biology, 2023, , 419-431.	0.4	0
1492	Future Perspectives for Developing Marine Drug Discovery. Marine Ecology, 2023, , 394-423.	0.1	0
1505	New drug discovery and development. , 2024, , 3-65.		0

# Article IF Citations